{"meta":{"query_hash":"c4752fabaa7c","filters":{"venue":"BioDrugs"},"cohort_total":53,"direct_labels_cover":0,"predictions_cover":53,"exported":53,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c4752fabaa7c","api":"https://metacan.xera.ac/api/v1/cohort?venue=BioDrugs"},"results":[{"id":"W137417466","doi":"10.2165/00063030-200519010-00005","title":"Antibody Induction Therapy in Renal Transplant Patients Receiving Calcineurin-Inhibitor Immunosuppressive Regimens","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Basiliximab; Daclizumab; Thymoglobulin; Calcineurin; Immunology; Internal medicine; Transplantation; Gastroenterology; Tacrolimus","score_opus":0.04379392079459723,"score_gpt":0.35726717048229173,"score_spread":0.3134732496876945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W137417466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066375514,0.9897069,0.000006959304,0.00006175387,0.00061732694,0.0018812708,0.00024903665,0.00007009961,0.0007691318],"genre_scores_gemma":[0.0026167904,0.99145216,0.00015230848,0.00005958078,0.00036060152,0.000104102175,0.004442061,0.00007872747,0.0007336444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974969,0.00017341122,0.00091265154,0.0005975973,0.00041440266,0.00040501874],"domain_scores_gemma":[0.99890906,0.000101038,0.00037614137,0.00039794508,0.0000718948,0.00014390121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012019681,0.0005908476,0.0015520196,0.00047000602,0.00007459424,0.000030633884,0.00013910618,0.00040152646,0.00009248483],"category_scores_gemma":[0.000011734774,0.00040968563,0.00054561417,0.0003842158,0.000046514397,0.00012641733,0.000012856472,0.0005318599,0.000110129244],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002445855,0.00075448584,0.003688534,0.0036302155,0.0005013567,0.00029108336,0.00049259886,5.2530845e-7,0.00007104014,0.000004899421,0.00006345756,0.9902572],"study_design_scores_gemma":[0.0078677945,0.0007028851,0.021344902,0.06625071,0.0012235031,0.00035460808,0.00001575329,0.0000014620863,0.00018950683,0.0000022511108,0.9013361,0.0007105699],"about_ca_topic_score_codex":0.00007156649,"about_ca_topic_score_gemma":0.000007782838,"teacher_disagreement_score":0.98954666,"about_ca_system_score_codex":0.00025287026,"about_ca_system_score_gemma":0.00018265613,"threshold_uncertainty_score":0.9998355},"labels":[],"label_agreement":null},{"id":"W1515001738","doi":"10.2165/00063030-200721020-00008","title":"Adalimumab in Crohn??s Disease","year":2007,"lang":"en","type":"article","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adalimumab; Crohn's disease; Medicine; Pharmacotherapy; Disease; Internal medicine","score_opus":0.006292762627965007,"score_gpt":0.24144955538876453,"score_spread":0.23515679276079954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515001738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618924,0.0003475413,0.00014911854,0.00006098983,0.0001420433,0.00015047888,0.000021028216,0.000017669385,0.0029218954],"genre_scores_gemma":[0.9982478,0.000017065555,0.00013851486,0.00049160304,0.00020910904,0.0000099203135,0.000065080574,0.000017195262,0.0008036839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991479,0.000025620966,0.00017240953,0.00025652332,0.0001100528,0.00028750725],"domain_scores_gemma":[0.99939907,0.000005340965,0.000034235167,0.00032592803,0.000030412357,0.00020503139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023545933,0.00011469948,0.00006367428,0.000058756108,0.00003379662,0.000012879242,0.00014300545,0.00007553805,0.000047636142],"category_scores_gemma":[0.00006967209,0.00011778272,0.00006678651,0.000070989656,0.000056748304,0.0000027687424,0.00006874567,0.000050392387,0.00009149981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052595763,0.0006407914,0.8114263,0.00014526096,0.00006610205,0.0067141843,0.00023914642,0.00007301105,0.13879071,0.0016967613,0.018168952,0.016779246],"study_design_scores_gemma":[0.0006344687,0.000011102348,0.97075695,0.000008693633,0.0000062174113,0.0000017368154,0.000039131603,0.00001121639,0.0058420314,0.000071351045,0.022443533,0.00017357538],"about_ca_topic_score_codex":0.000011190684,"about_ca_topic_score_gemma":0.00009375948,"teacher_disagreement_score":0.15933068,"about_ca_system_score_codex":0.000021614947,"about_ca_system_score_gemma":0.00009474911,"threshold_uncertainty_score":0.480304},"labels":[],"label_agreement":null},{"id":"W1778153929","doi":"10.1007/s40259-015-0144-3","title":"Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Apremilast; Psoriasis; Medicine; Proinflammatory cytokine; Pharmacology; Tumor necrosis factor alpha; Immunology; Tofacitinib; Phosphodiesterase; Inflammation; Psoriatic arthritis; Rheumatoid arthritis; Chemistry","score_opus":0.0367836431140947,"score_gpt":0.31696843569433947,"score_spread":0.28018479258024476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1778153929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004654637,0.99436903,0.00017571969,0.000041677802,0.0019436509,0.0014504412,0.0003610745,0.000049564394,0.0015622784],"genre_scores_gemma":[0.0002243368,0.99152225,0.00020857739,0.00013448011,0.0018663823,0.0006428736,0.0017419603,0.00011210341,0.0035470333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980489,0.000117977645,0.00050243904,0.0007656638,0.00021038787,0.00035462325],"domain_scores_gemma":[0.99867815,0.000047060403,0.00035838108,0.0005084896,0.00022846111,0.0001794809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029656047,0.0005604554,0.00085984997,0.00012992544,0.00012884018,0.000052195537,0.00021332286,0.0006760303,0.000008240345],"category_scores_gemma":[0.00013030633,0.0004466939,0.00059698796,0.0001889149,0.00007106714,0.000004908491,0.00008845295,0.00018013344,0.00007994648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002365489,0.00012074276,0.0000022211827,0.0015428822,0.00029245904,0.000001346071,0.00005153038,0.0000034494672,0.00008794056,0.00005997056,0.15215042,0.84545046],"study_design_scores_gemma":[0.0006944996,0.00051437446,0.0000011153404,0.001264296,0.00027544698,0.00001242264,0.000024022549,0.0000022371808,0.0035004097,0.000056815865,0.9931316,0.00052277604],"about_ca_topic_score_codex":0.000007772774,"about_ca_topic_score_gemma":0.000010141182,"teacher_disagreement_score":0.8449277,"about_ca_system_score_codex":0.00014871126,"about_ca_system_score_gemma":0.0004196766,"threshold_uncertainty_score":0.9997985},"labels":[],"label_agreement":null},{"id":"W183087027","doi":"10.2165/00063030-200418050-00004","title":"Islet Transplantation in Patients with Diabetes Mellitus","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immunosuppression; Transplantation; Azathioprine; Diabetes mellitus; Tacrolimus; Sirolimus; Type 1 diabetes; Insulin; Islet; Everolimus; Organ transplantation; Immunology; Intensive care medicine; Internal medicine; Endocrinology; Disease","score_opus":0.015294381505291369,"score_gpt":0.25792639036646875,"score_spread":0.2426320088611774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W183087027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051206346,0.99217004,0.0000032059118,0.000019421454,0.00013981895,0.00087880006,0.00008571464,0.00005251416,0.0015298367],"genre_scores_gemma":[0.00042278552,0.9974106,0.00020253749,0.00010644141,0.00006605587,0.00008113845,0.0014545455,0.000036860187,0.00021903538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880594,0.00004586285,0.00036259784,0.00029409,0.00024505844,0.00024647304],"domain_scores_gemma":[0.99942756,0.00007707076,0.00012900848,0.00022591601,0.00004125382,0.00009921446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084623425,0.000288675,0.0010811139,0.00025823168,0.000021366557,0.0000133622025,0.000057054298,0.00019633146,0.0001244028],"category_scores_gemma":[0.000025196225,0.0001886288,0.00015249928,0.00033752414,0.000044375385,0.000046323596,0.0000054509783,0.00019534884,0.00019936355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009835164,0.00051866216,0.011218614,0.068900034,0.00026984286,0.000023172694,0.00014718632,4.4926819e-7,5.4761597e-7,0.000068115674,0.0002907984,0.91846424],"study_design_scores_gemma":[0.004442223,0.00045012907,0.0059081563,0.056633078,0.0019597367,0.0000026150951,0.000008123702,6.199408e-7,0.00001940082,0.000014640397,0.9301366,0.0004246281],"about_ca_topic_score_codex":0.000011907475,"about_ca_topic_score_gemma":9.352783e-7,"teacher_disagreement_score":0.92984587,"about_ca_system_score_codex":0.00016172121,"about_ca_system_score_gemma":0.00024033987,"threshold_uncertainty_score":0.76920587},"labels":[],"label_agreement":null},{"id":"W1965655787","doi":"10.2165/00063030-200519010-00004","title":"Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Riluzole; Amyotrophic lateral sclerosis; Glial cell line-derived neurotrophic factor; SOD1; Excitotoxicity; Neurodegeneration; Neurotrophic factors; Medicine; Oxidative stress; Neuroprotection; Pharmacology; Vascular endothelial growth factor; Glutamate receptor; Biology; Disease; Pathology; Cancer research; Internal medicine; Receptor","score_opus":0.5004309636387372,"score_gpt":0.4003231433586333,"score_spread":0.1001078202801039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965655787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023498507,0.9910279,0.0000020534367,0.0022089058,0.00019805005,0.0035487774,0.00012383403,0.000066778506,0.00047385617],"genre_scores_gemma":[0.0017485999,0.9921564,0.0003652835,0.00018475056,0.0012134606,0.00085392565,0.00011304109,0.00008007082,0.003284488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702585,0.00030500419,0.000781184,0.0006468235,0.0005962113,0.0006449126],"domain_scores_gemma":[0.99836516,0.00013792819,0.0002511079,0.00084108574,0.000063276275,0.00034140964],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002640594,0.0006032028,0.0021152524,0.00028293574,0.0001143064,0.000039863535,0.0004924303,0.00034449532,0.00062792934],"category_scores_gemma":[0.000022167773,0.00028778237,0.0009905406,0.00071325083,0.00019262724,0.000039547544,0.00013642378,0.0003356125,0.0009358005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006743216,0.0006126748,0.000015813932,0.0018653318,0.0005053112,0.0000133510885,0.00022105762,0.0000024682745,0.000030282106,0.000017737719,0.0019201667,0.9947284],"study_design_scores_gemma":[0.0007226206,0.0011099724,0.00047242432,0.0026621267,0.0013320959,0.000027438477,0.000007079207,0.000014646841,0.000025695392,0.000001778731,0.99336374,0.00026039622],"about_ca_topic_score_codex":0.000094530005,"about_ca_topic_score_gemma":0.000006344277,"teacher_disagreement_score":0.994468,"about_ca_system_score_codex":0.0007227728,"about_ca_system_score_gemma":0.0003131818,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W1976055108","doi":"10.2165/00063030-200317040-00006","title":"Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Basiliximab; Medicine; Transplantation; Internal medicine; Azathioprine; Placebo; Kidney transplantation; Gastroenterology; Surgery; Pathology","score_opus":0.1943935681286605,"score_gpt":0.39863552428444543,"score_spread":0.20424195615578494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976055108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021062022,0.99627006,0.0003186879,0.000011865349,0.00005880434,0.001389662,0.0015323838,0.000010641366,0.00038683595],"genre_scores_gemma":[0.00010948904,0.9930032,0.002084641,0.000027551689,0.000009533963,0.00034989318,0.003083918,0.000030180392,0.0013016273],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99804467,0.00011131788,0.0010169819,0.00037449572,0.00026224434,0.00019031909],"domain_scores_gemma":[0.9989203,0.00024485376,0.00037192987,0.000329277,0.000075047654,0.000058562808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002457548,0.00035153134,0.004268648,0.00097577,0.000021701591,0.000008510068,0.00008848826,0.00021278062,0.00024803518],"category_scores_gemma":[0.000007803534,0.00022628473,0.004541533,0.0011416823,0.00003163689,0.00003581728,0.000002550189,0.00011679049,0.0000101403775],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031672075,0.00067277445,0.000095656476,0.076825775,0.7099204,0.000110650544,0.00030137843,0.000008480794,0.000008974102,0.00030764838,0.000015546939,0.21141598],"study_design_scores_gemma":[0.0013828508,0.0001674196,0.000116188254,0.0010779474,0.86688364,0.000027199394,0.0000061531073,0.000004173455,0.000043826527,0.000008919278,0.13008979,0.00019191232],"about_ca_topic_score_codex":0.00007351897,"about_ca_topic_score_gemma":0.000024023859,"teacher_disagreement_score":0.21122406,"about_ca_system_score_codex":0.00007427835,"about_ca_system_score_gemma":0.00015129741,"threshold_uncertainty_score":0.92276233},"labels":[],"label_agreement":null},{"id":"W1983049039","doi":"10.2165/00063030-200822030-00002","title":"Developing Therapeutic Immunoglobulins","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Indigenous and Northern Affairs Canada","keywords":"Medicine; Immunology; Antibody; Thrombocytopenic purpura; Disease; Immune system; Internal medicine","score_opus":0.060472512308744834,"score_gpt":0.31447269742110623,"score_spread":0.2540001851123614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983049039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004666497,0.9943185,0.00008626165,0.000033422093,0.0021822744,0.00056106574,0.000052302858,0.00023154455,0.002529978],"genre_scores_gemma":[0.000073135416,0.9944975,0.000030031602,0.00014402052,0.000011052692,0.00009710152,0.000761757,0.00007562063,0.0043097795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742675,0.00033661,0.00086402363,0.000581919,0.000056073975,0.00073462544],"domain_scores_gemma":[0.9986188,0.00017603292,0.00041623908,0.00072941266,0.000053226482,0.0000063230154],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001518355,0.0007086498,0.0017610925,0.00027174666,0.0005709571,0.000028853643,0.00093235174,0.0009534744,0.00037971718],"category_scores_gemma":[0.000034589437,0.000558648,0.00088472886,0.0004941515,0.00040245982,0.00007487443,0.000199224,0.0008001378,0.009056988],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053891345,0.000062736544,3.0637685e-7,0.0009855219,0.00046010295,0.0000069518574,0.00018227947,4.3796135e-8,0.000023169125,0.001315543,0.0004981143,0.99645984],"study_design_scores_gemma":[0.00032404423,0.00003105657,0.0000063193065,0.0027495478,0.00023540226,0.0004750156,0.00007590971,4.3800362e-8,0.000035530866,0.000042801294,0.99531466,0.0007096564],"about_ca_topic_score_codex":0.000055204066,"about_ca_topic_score_gemma":3.8113023e-7,"teacher_disagreement_score":0.9957502,"about_ca_system_score_codex":0.00016346198,"about_ca_system_score_gemma":0.0008484063,"threshold_uncertainty_score":0.9996865},"labels":[],"label_agreement":null},{"id":"W1989638496","doi":"10.1007/s40259-013-0072-z","title":"Interferon-Free Regimens for Hepatitis C: Combine and Conquer","year":2013,"lang":"en","type":"review","venue":"BioDrugs","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Association for the Study of the Liver; Genentech; Bayer HealthCare","keywords":"Telaprevir; Boceprevir; Medicine; Sofosbuvir; Pegylated interferon; Hepatitis C; Internal medicine; Daclatasvir; Hepatitis C virus; Dolutegravir; Interferon; Immunology; Ribavirin; Intensive care medicine; Viral load; Human immunodeficiency virus (HIV); Virus; Antiretroviral therapy","score_opus":0.12256526697449986,"score_gpt":0.4082298027057468,"score_spread":0.28566453573124695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989638496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003419476,0.9893711,0.000038749582,0.0005755614,0.00026536404,0.0041055763,0.00068484695,0.000083118626,0.0048414893],"genre_scores_gemma":[0.000013264398,0.9816599,0.0012146656,0.0002060629,0.00031532726,0.0010620896,0.00064608495,0.00012023503,0.01476237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978527,0.00011837003,0.0006150085,0.0005660091,0.0003378461,0.00051005994],"domain_scores_gemma":[0.9978317,0.00039367212,0.00018612339,0.0009880012,0.00023229093,0.00036818557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032497488,0.00044321973,0.0019504144,0.0002938099,0.00007468242,0.00007251347,0.00031602345,0.0004363062,0.00062493025],"category_scores_gemma":[0.00053914025,0.00033703254,0.00032492762,0.00017801578,0.00024040189,0.00007012182,0.0003308805,0.0004579644,0.00062541716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014627269,0.000045404297,0.000053968546,0.016933592,0.00022060964,0.000020330184,0.00003188552,3.662623e-10,0.0000017754644,0.0002793808,0.19689797,0.78550047],"study_design_scores_gemma":[0.0011915427,0.00058532873,0.000009666783,0.0087777395,0.00049172045,0.00005790514,0.0000056893164,0.000010588887,0.000008124315,0.00006577721,0.98849314,0.0003027938],"about_ca_topic_score_codex":0.0006847195,"about_ca_topic_score_gemma":0.00007330019,"teacher_disagreement_score":0.79159516,"about_ca_system_score_codex":0.00020113523,"about_ca_system_score_gemma":0.00037840512,"threshold_uncertainty_score":0.99990815},"labels":[],"label_agreement":null},{"id":"W1990941062","doi":"10.2165/00063030-200822040-00005","title":"Anti-Adhesion Molecule Strategies for Crohn Disease","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Infliximab; Crohn's disease; Adalimumab; Medicine; Monoclonal antibody; Disease; Tumor necrosis factor alpha; Monoclonal antibody therapy; Inflammatory bowel disease; Immunology; Monoclonal; Certolizumab pegol; Antibody; Internal medicine","score_opus":0.025001312585896676,"score_gpt":0.3008105274606349,"score_spread":0.27580921487473825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990941062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009914383,0.99599653,0.00015630087,0.000007636471,0.0002852363,0.0013204187,0.00076062145,0.000044818953,0.0004369863],"genre_scores_gemma":[0.00024160885,0.99507827,0.0001780398,0.00009512709,0.00063973,0.00041883998,0.0024310797,0.00011442664,0.0008028579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981248,0.0001073659,0.0004450233,0.0007276082,0.00017423631,0.0004209987],"domain_scores_gemma":[0.998539,0.000016993461,0.00025090014,0.00079025334,0.00010480506,0.00029810125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007782197,0.00054306973,0.0006743632,0.000092921386,0.00016524809,0.00007208381,0.00042927693,0.00039611352,0.000020710399],"category_scores_gemma":[0.000080783175,0.00048041187,0.0009471261,0.00008328376,0.00013405111,0.000006272237,0.00015028293,0.000111172434,0.00010792331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085750694,0.0009131284,0.00009119441,0.08042689,0.0013732545,0.0040226886,0.00008684079,0.000018370727,0.0010150869,0.0017925043,0.30342957,0.60597295],"study_design_scores_gemma":[0.00027796804,0.000033179218,0.00025724233,0.0008822642,0.00029459503,0.000015120768,0.000010970072,0.0000029054513,0.000042053052,0.000028965937,0.99755734,0.0005973867],"about_ca_topic_score_codex":0.0000022135123,"about_ca_topic_score_gemma":0.0000014757954,"teacher_disagreement_score":0.6941278,"about_ca_system_score_codex":0.000032179672,"about_ca_system_score_gemma":0.0014592955,"threshold_uncertainty_score":0.99976474},"labels":[],"label_agreement":null},{"id":"W2007886942","doi":"10.2165/00063030-200013040-00004","title":"Use of Thalidomide in Dermatological Indications","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Thalidomide; Medicine; Adverse effect; Immunology; Pharmacology; Drug; Disease; Internal medicine; Multiple myeloma","score_opus":0.07712116623729452,"score_gpt":0.3360419291086052,"score_spread":0.25892076287131066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007886942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506825,0.0000935002,0.0000028308627,0.00079267815,0.000005696573,0.00021265916,0.000016180089,0.000015060901,0.0037931597],"genre_scores_gemma":[0.9978416,0.00012934401,0.0010427895,0.0001043079,0.000007814808,0.000020142606,0.000036178004,0.0000036497004,0.00081416254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946326,0.000032117583,0.00013977627,0.00009774783,0.00012954017,0.00013758196],"domain_scores_gemma":[0.99965334,0.000072486655,0.00001748213,0.00015279248,0.000017035354,0.00008684253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004058333,0.000049482733,0.00013276745,0.00008636543,0.000017189564,0.000004627775,0.000036793856,0.000044324875,0.0010526292],"category_scores_gemma":[0.00007997454,0.000035586396,0.000036717607,0.0001549359,0.00006269548,0.000040998737,0.000009894226,0.00006239244,0.00020121552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002725813,0.00055832235,0.96743876,0.00002135501,0.000034284127,0.00014126206,0.00014891084,0.0000010815761,0.0010833842,0.00026251187,0.0007218084,0.029315718],"study_design_scores_gemma":[0.00163615,0.00005314669,0.98108864,0.000033712207,0.000010772004,0.0000419839,0.000021768348,0.00010400456,0.0063099046,0.00005166621,0.01060881,0.00003942905],"about_ca_topic_score_codex":0.00020792028,"about_ca_topic_score_gemma":0.0000165417,"teacher_disagreement_score":0.029276287,"about_ca_system_score_codex":0.00002250302,"about_ca_system_score_gemma":0.00004281127,"threshold_uncertainty_score":0.9998605},"labels":[],"label_agreement":null},{"id":"W2009690780","doi":"10.2165/00063030-200418020-00001","title":"Business Ethics 101 for the Biotech Industry","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Mary's University","funders":"","keywords":"Drug industry; Business ethics; Business; Management; Biotechnology; Engineering ethics; Medicine; Biology; Engineering; Economics","score_opus":0.12002475341069896,"score_gpt":0.3866064633007289,"score_spread":0.26658170989002994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009690780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.228124e-7,0.947875,0.00037579358,0.048812293,0.0009797574,0.0013891897,0.000045379176,0.0001799113,0.00034211285],"genre_scores_gemma":[0.000004170287,0.9945615,0.00035587946,0.0010156834,0.0004271728,0.00012626623,0.00010061763,0.00005336283,0.0033553275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870586,0.000038779042,0.00040291008,0.00036719456,0.0001691894,0.0003160602],"domain_scores_gemma":[0.99842095,0.00044923092,0.00020941936,0.00071351527,0.00014080037,0.000066089946],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00047373242,0.0003567002,0.0010058512,0.00017596896,0.00025434454,0.0000163696,0.00035814045,0.042456,0.00007087997],"category_scores_gemma":[0.00048073236,0.00018489732,0.00042441647,0.0007848548,0.00039197528,0.000016250553,0.000092544105,0.018709244,0.00014425717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015555615,0.00007414039,4.3480432e-7,0.02679363,0.0005545784,0.000026867541,0.00005195579,1.8807033e-7,0.0000011813809,0.003898184,0.0054357434,0.9631475],"study_design_scores_gemma":[0.0003828443,0.000047871756,0.0000031778848,0.02063849,0.0022204535,0.00030560064,0.00002729518,8.229423e-7,0.000019486468,0.00008412958,0.9760547,0.00021507869],"about_ca_topic_score_codex":0.000028373597,"about_ca_topic_score_gemma":0.000001722099,"teacher_disagreement_score":0.970619,"about_ca_system_score_codex":0.00009759984,"about_ca_system_score_gemma":0.0015146782,"threshold_uncertainty_score":0.98355466},"labels":[],"label_agreement":null},{"id":"W2012092068","doi":"10.2165/00063030-200317001-00006","title":"Current Status and Replies to Frequently Posed Questions on Atovaquone Plus Proguanil (Malarone??) for the Prevention of Malaria","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Malaria Research and Control","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Proguanil; Malaria; Atovaquone; Mefloquine; Medicine; Chloroquine; Chemoprophylaxis; Malaria prophylaxis; Artemisinin; Intensive care medicine; Primaquine; Plasmodium falciparum; Pharmacology; Immunology; Internal medicine","score_opus":0.07494769191811303,"score_gpt":0.39599828050135083,"score_spread":0.3210505885832378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012092068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037159014,0.9890766,0.00045177675,0.0010247584,0.00027199744,0.008521314,0.00030958722,0.000033864108,0.00027291325],"genre_scores_gemma":[0.00028627322,0.9945404,0.00068181055,0.000063462576,0.00021142447,0.0017947729,0.00023686308,0.0000485736,0.0021364042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773103,0.00021756194,0.0006321962,0.0004993082,0.00043685525,0.00048303322],"domain_scores_gemma":[0.99816537,0.00033089015,0.0002921193,0.0006983045,0.00022834272,0.0002850017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074747583,0.00034896008,0.0011917453,0.00024547224,0.00012870143,0.00004755938,0.00016495235,0.00019215365,0.00007452433],"category_scores_gemma":[0.00065862114,0.00021450272,0.00040847395,0.00029829156,0.0000965957,0.000036635138,0.00006134489,0.0004002332,0.000030136895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037181424,0.00027526656,0.000008306384,0.014266706,0.0004624374,0.0000035638197,0.000077810895,3.3922677e-7,0.000021293323,0.019685294,0.0024044598,0.9624227],"study_design_scores_gemma":[0.0015834206,0.001031648,0.00019414644,0.008925906,0.0013584412,0.00001625448,0.000031695305,0.00001184686,0.000012551361,0.00016324797,0.98647517,0.00019567544],"about_ca_topic_score_codex":0.000057438603,"about_ca_topic_score_gemma":0.000021110087,"teacher_disagreement_score":0.9840707,"about_ca_system_score_codex":0.00021954492,"about_ca_system_score_gemma":0.001156171,"threshold_uncertainty_score":0.8747167},"labels":[],"label_agreement":null},{"id":"W2015187915","doi":"10.2165/00063030-200822040-00002","title":"Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Insulin; Glycemic; Gastrointestinal tract; Nanoparticle; Diabetes mellitus; Nanotechnology; Pharmacology; Medicine; Chemistry; Materials science; Internal medicine; Endocrinology","score_opus":0.15896326056502963,"score_gpt":0.4157631336086455,"score_spread":0.25679987304361584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015187915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035090058,0.9940527,0.0005231654,0.00009379741,0.00040566214,0.00110051,0.00016598357,0.000071764676,0.000077415454],"genre_scores_gemma":[0.033481665,0.9654304,0.0005986194,0.000073025156,0.0001585561,0.000110317036,0.000056437286,0.000039944254,0.000051062085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974254,0.00068482937,0.000935242,0.00040850812,0.00015585056,0.00039018685],"domain_scores_gemma":[0.99841934,0.00047739624,0.0005704849,0.00025326613,0.00014552848,0.00013399347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040893262,0.0004595673,0.0010470322,0.00010925966,0.0001720303,0.00002319084,0.0003738986,0.0004232282,0.00006285225],"category_scores_gemma":[0.000034102894,0.00032249422,0.00025702504,0.0002691129,0.0006122992,0.0001662509,0.00007176539,0.000945627,0.000057614463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000963452,0.00010700369,0.000016705362,0.0027181644,0.00017422912,0.000018007451,0.0006967154,0.000026587462,0.001861975,0.0001401285,0.0003419726,0.9938022],"study_design_scores_gemma":[0.0007313102,0.00018705559,0.000028257982,0.0012759509,0.000566077,0.0008736476,0.00062331615,0.0011183617,0.0004972541,0.000033249802,0.9936705,0.00039499957],"about_ca_topic_score_codex":0.00007709486,"about_ca_topic_score_gemma":0.00002603593,"teacher_disagreement_score":0.9934072,"about_ca_system_score_codex":0.000063291816,"about_ca_system_score_gemma":0.00040728002,"threshold_uncertainty_score":0.9999227},"labels":[],"label_agreement":null},{"id":"W2016399234","doi":"10.2165/00063030-200923010-00002","title":"MicroRNA-Based Therapeutics for Cancer","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"microRNA; Biology; Translation (biology); Oncomir; Cancer; Signal transduction; Computational biology; Cancer research; Bioinformatics; Gene; Messenger RNA; Cell biology; Genetics","score_opus":0.048097010165034176,"score_gpt":0.3556908438159273,"score_spread":0.3075938336508931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016399234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025324354,0.9975163,0.0005745248,0.000067226145,0.00021886358,0.00096998585,0.00054337626,0.000019664747,0.000064750246],"genre_scores_gemma":[0.000019488227,0.99503326,0.0009397689,0.00040711949,0.0006692092,0.00026338507,0.0020247782,0.00006887394,0.0005741075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998815,0.000057755413,0.00031921171,0.0004572803,0.000087334935,0.0002633956],"domain_scores_gemma":[0.99908656,0.000017290518,0.00025766608,0.0004805819,0.00008952681,0.00006837271],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000099691286,0.00034891412,0.0005284014,0.00006493483,0.000058657508,0.000030374198,0.0002804858,0.00046951807,0.000019401756],"category_scores_gemma":[0.0000126658615,0.00030120858,0.000597664,0.00009093767,0.000045300814,0.0000010198199,0.000028514167,0.00007348973,0.000015989326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019073243,0.00004885496,9.802221e-7,0.0029728038,0.00016926907,4.4558237e-7,0.0000022376028,0.0000020607908,0.0046709683,0.000009887569,0.0068413913,0.98526204],"study_design_scores_gemma":[0.00024180577,0.000056791254,0.000002959658,0.0010924975,0.00060821057,0.000002234892,7.7080534e-7,0.0000060156895,0.003847161,0.000009459916,0.99377316,0.00035894816],"about_ca_topic_score_codex":0.0000035041412,"about_ca_topic_score_gemma":0.0000057839397,"teacher_disagreement_score":0.98693174,"about_ca_system_score_codex":0.00006287766,"about_ca_system_score_gemma":0.00058385014,"threshold_uncertainty_score":0.99994403},"labels":[],"label_agreement":null},{"id":"W2024217378","doi":"10.2165/00063030-200014020-00006","title":"Photodynamic Therapy in Immune (Non-Oncological) Disorders","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; QLT (Canada)","funders":"","keywords":"Photodynamic therapy; Verteporfin; Medicine; Immune system; Cancer research; Immunology; Chemistry; Surgery","score_opus":0.011536345573356716,"score_gpt":0.30031890629598984,"score_spread":0.28878256072263314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024217378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97506374,0.0019881807,0.0000018115732,0.001937204,0.00006337225,0.0009057527,0.000008896205,0.000091544585,0.019939525],"genre_scores_gemma":[0.97847104,0.015884623,0.00008462708,0.0005449488,0.000045664674,0.00015048469,0.00002004791,0.000023927512,0.004774654],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853235,0.000066733955,0.00028927444,0.000333788,0.00028174938,0.00049607316],"domain_scores_gemma":[0.9993848,0.000091523056,0.000033656845,0.0003591046,0.000025726324,0.000105142506],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029278157,0.00020393907,0.00040817686,0.0001480832,0.00007909493,0.000013805768,0.0001865527,0.00010913355,0.0024259244],"category_scores_gemma":[0.00003391671,0.00014990018,0.00013886308,0.0004307175,0.00022650485,0.000058046466,0.00003471798,0.00030520864,0.00025616592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030235306,0.0014719344,0.010076358,0.000045706714,0.00020320588,0.00011213447,0.0018376727,0.000012756497,0.3583437,0.000025467034,0.0009054766,0.6239421],"study_design_scores_gemma":[0.012159734,0.0023264803,0.8778387,0.0001491033,0.00001715619,0.000030417053,0.00061166345,0.0009124284,0.0115179345,0.0008251075,0.09309099,0.0005202982],"about_ca_topic_score_codex":0.00056677195,"about_ca_topic_score_gemma":0.00014209987,"teacher_disagreement_score":0.8677623,"about_ca_system_score_codex":0.00018946444,"about_ca_system_score_gemma":0.00009854324,"threshold_uncertainty_score":0.998486},"labels":[],"label_agreement":null},{"id":"W2029930411","doi":"10.1007/s40259-014-0099-9","title":"Similar Names for Similar Biologics","year":2014,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amicus Therapeutics; Amgen","keywords":"Biosimilar; Pharmacovigilance; Interchangeability; Medicine; Product (mathematics); Pharmacology; Computer science; Adverse effect","score_opus":0.022341485618954108,"score_gpt":0.2784489941231749,"score_spread":0.2561075085042208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029930411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4015887,0.04277906,0.2887388,0.12480361,0.02718434,0.0078818565,0.0034305085,0.0038887693,0.09970435],"genre_scores_gemma":[0.9499135,0.00023024001,0.029784257,0.009940424,0.00036820752,0.00007618874,0.00017217667,0.000045701974,0.009469297],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985956,0.00021212343,0.00028252008,0.0004071515,0.000026265638,0.00047634382],"domain_scores_gemma":[0.99888146,0.00055816263,0.000089680296,0.00034262467,0.00008589441,0.000042154603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076197437,0.00022255727,0.00036233614,0.00006401271,0.00019616829,0.00001958278,0.00029445524,0.00047788268,0.0005089776],"category_scores_gemma":[0.0005686913,0.00015739347,0.00022194028,0.00012004379,0.0003162359,0.000035546942,0.000080966805,0.00018022534,0.00020271953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005442615,0.00048569954,0.0050324854,0.00014273301,0.00056242244,0.0000024461817,0.00020057421,0.0000051682105,0.47323257,0.05878359,0.29074103,0.17026705],"study_design_scores_gemma":[0.0008044739,0.00037010282,0.00080272794,0.000012346111,0.000066463144,0.0000064303654,0.00005108788,0.00009696518,0.10155871,0.0060550086,0.8899129,0.00026278858],"about_ca_topic_score_codex":0.000005714773,"about_ca_topic_score_gemma":0.0000030020124,"teacher_disagreement_score":0.5991719,"about_ca_system_score_codex":0.00001785701,"about_ca_system_score_gemma":0.000022250611,"threshold_uncertainty_score":0.641832},"labels":[],"label_agreement":null},{"id":"W2030438860","doi":"10.2165/11206830-000000000-00000","title":"Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†","year":2011,"lang":"en","type":"article","venue":"BioDrugs","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunogenicity; Medicine; Cervical cancer; Virology; Adjuvant; Immunology; Cervical intraepithelial neoplasia; HPV vaccines; DNA vaccination; Immune system; Vaccination; HPV infection; Immunization; Cancer; Internal medicine","score_opus":0.08524794751241882,"score_gpt":0.3382199901668697,"score_spread":0.2529720426544509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030438860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5450166,0.0018395203,0.000008848354,0.001227278,0.00017154148,0.00044449445,0.000027203323,0.00017493672,0.45108956],"genre_scores_gemma":[0.99164385,0.00029178613,0.000091144226,0.0013120621,0.00029307368,0.000015846725,0.000031110292,0.00003499727,0.0062861573],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872416,0.000036141744,0.00021849891,0.00035643243,0.00031587275,0.00034891066],"domain_scores_gemma":[0.9991372,0.000037431993,0.000040515344,0.0003737741,0.00011701004,0.00029403853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001803717,0.00018057441,0.0003230951,0.00014827435,0.00012529953,0.000021195274,0.00011898647,0.00011959088,0.028674537],"category_scores_gemma":[0.00003846074,0.00013400866,0.00007449667,0.00020699532,0.00007378358,0.00005163529,0.00009108372,0.0002632404,0.00054716936],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012054734,0.0026444315,0.101545535,0.0011767691,0.0007333141,0.00076282,0.003106782,1.10558894e-7,0.024166426,0.026967276,0.14034101,0.6865008],"study_design_scores_gemma":[0.0042890413,0.0014579264,0.8746372,0.000053225765,0.0001033149,0.000031005406,0.00011955704,0.000012429455,0.028536675,0.0012561758,0.08922437,0.0002790748],"about_ca_topic_score_codex":0.00076971384,"about_ca_topic_score_gemma":0.00013258921,"teacher_disagreement_score":0.7730917,"about_ca_system_score_codex":0.0000797147,"about_ca_system_score_gemma":0.00004686261,"threshold_uncertainty_score":0.9722134},"labels":[],"label_agreement":null},{"id":"W2047330433","doi":"10.2165/00063030-200923020-00002","title":"Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Howard Hughes Medical Institute","keywords":"PI3K/AKT/mTOR pathway; Sirolimus; Protein kinase B; Cancer; Cancer research; RPTOR; Signal transduction; Pharmacology; Biology; Medicine; Internal medicine; Cell biology","score_opus":0.07859009767915429,"score_gpt":0.35351198432365355,"score_spread":0.27492188664449924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047330433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032570446,0.9979364,0.000017132528,0.000058295223,0.0003571136,0.00081754156,0.00041478852,0.000026560821,0.000046439167],"genre_scores_gemma":[0.00009517086,0.99759084,0.00014046728,0.00005486176,0.00081819005,0.0004235401,0.00068791304,0.000079803685,0.000109196466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828327,0.00010438308,0.00031044497,0.0006715255,0.0001550226,0.0004753436],"domain_scores_gemma":[0.9990401,0.000058380447,0.00037811502,0.00026946224,0.00013592177,0.00011799359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002578892,0.00045593275,0.0007832593,0.000054984208,0.00008761962,0.000036734626,0.00019763653,0.00036452632,0.000009814229],"category_scores_gemma":[0.00007406147,0.00033665547,0.00020898056,0.00008064106,0.000072420145,0.0000029042037,0.000044130997,0.00017234746,0.0000012913549],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033821536,0.000049052956,0.000015412481,0.0016707941,0.00030903256,5.279077e-7,0.000037085243,4.910814e-7,0.000098891804,0.0000086403725,0.001948787,0.99582744],"study_design_scores_gemma":[0.00053328415,0.0003693032,0.000016291482,0.0031123438,0.0001897517,0.0000012545939,0.0000105094405,0.0000010383066,0.0002327621,0.00000790609,0.99505204,0.00047352182],"about_ca_topic_score_codex":0.000012236389,"about_ca_topic_score_gemma":0.000028632467,"teacher_disagreement_score":0.99535394,"about_ca_system_score_codex":0.00009652038,"about_ca_system_score_gemma":0.00051426335,"threshold_uncertainty_score":0.99990857},"labels":[],"label_agreement":null},{"id":"W204758488","doi":"10.2165/00063030-200721010-00002","title":"Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome","year":2007,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Small interfering RNA; RNA interference; Virology; RNA; Biology; Medicine; Coronavirus; Immunology; Coronavirus disease 2019 (COVID-19); Gene; Infectious disease (medical specialty); Pathology; Disease","score_opus":0.0431896343897843,"score_gpt":0.3051160456634367,"score_spread":0.2619264112736524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W204758488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034895387,0.9638144,0.00015241175,0.0000037101975,0.00030278903,0.00039924518,0.000088541296,0.00001228624,0.0003312588],"genre_scores_gemma":[0.020751981,0.97809374,0.00009852349,0.00013216796,0.00016854989,0.000021603782,0.00012594108,0.000057153848,0.0005503492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840593,0.00009605077,0.0005363322,0.0005352851,0.00012513781,0.00030123463],"domain_scores_gemma":[0.998999,0.000012860034,0.00032778762,0.0004843254,0.00008328923,0.000092728216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020952459,0.00041051192,0.0007826927,0.00016416852,0.000048278584,0.00003395229,0.00035839976,0.0005013557,0.000010101923],"category_scores_gemma":[0.000012366118,0.00034050058,0.00035448762,0.00011237703,0.000134256,0.0000046397267,0.00026154603,0.00024208444,0.00002087093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065404056,0.000051570638,0.000008315864,0.003994962,0.0007263802,0.000098574405,0.000022128612,6.3791776e-7,0.014802469,0.0000040155387,0.000091229864,0.9801343],"study_design_scores_gemma":[0.00038760022,0.0010673668,0.000046312238,0.002990234,0.0009188935,0.0006082883,0.000038182447,0.000002333706,0.0046404926,0.000007403347,0.98850304,0.0007898368],"about_ca_topic_score_codex":0.0000072590733,"about_ca_topic_score_gemma":0.0000045295237,"teacher_disagreement_score":0.98841184,"about_ca_system_score_codex":0.000025553723,"about_ca_system_score_gemma":0.00019248022,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W2052842550","doi":"10.2165/00063030-200115120-00005","title":"Current and Future Applications of Immunological Attenuation via Pegylation of Cells and Tissue","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Transplantation; PEGylation; Immune system; Immunology; Immunosuppression; Immunogenicity; Immunologic Tolerance; Antigenicity; Alloimmunity; Antibody; Medicine; In vivo; Immune tolerance; Cancer research; Biology; Internal medicine","score_opus":0.029765588536721496,"score_gpt":0.32197767037472635,"score_spread":0.29221208183800484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052842550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042070672,0.9979688,0.0003283874,0.00004248115,0.00009533063,0.00071533903,0.000041846353,0.000013975647,0.0003731212],"genre_scores_gemma":[0.00019823114,0.99880314,0.00035818407,0.0000064075,0.00021170001,0.000058633508,0.00023446418,0.000008090254,0.00012112973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999249,0.000039593095,0.00035702213,0.00017510174,0.00010749622,0.000071790906],"domain_scores_gemma":[0.9993441,0.00008334175,0.0002804735,0.00017012401,0.00007525935,0.00004671208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009604036,0.00013688063,0.0007029363,0.000121618774,0.000021810609,0.0000035982143,0.000029118022,0.00017268429,0.00008321461],"category_scores_gemma":[0.000015140496,0.00009789688,0.00006678989,0.00021117159,0.00008681405,0.000019495701,0.000021158437,0.00010827219,0.000010002413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054410007,0.000057774236,0.000064285734,0.0057486994,0.000034334913,1.3813991e-7,0.00002572124,6.4341075e-9,0.00025542692,0.00009304507,0.00012527051,0.9935899],"study_design_scores_gemma":[0.0002423046,0.00008524218,0.00047230948,0.0012983283,0.0006156414,0.000011720469,0.000025049323,0.0000038438584,0.00015326947,0.00002360109,0.99699223,0.00007647168],"about_ca_topic_score_codex":0.0000064876613,"about_ca_topic_score_gemma":1.6517934e-7,"teacher_disagreement_score":0.99686694,"about_ca_system_score_codex":0.000018405448,"about_ca_system_score_gemma":0.000043320382,"threshold_uncertainty_score":0.3992119},"labels":[],"label_agreement":null},{"id":"W2061784015","doi":"10.2165/11539070-000000000-00000","title":"Systemic and Mucosal Delivery of Drugs within Polymeric Microparticles Produced by Spray Drying","year":2010,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Spray drying; Drug delivery; Controlled release; Drug; Dosage form; Chitosan; Pharmacology; Nanotechnology; Materials science; Chemistry; Medicine; Chromatography; Organic chemistry","score_opus":0.020817535020426242,"score_gpt":0.29111167183393394,"score_spread":0.27029413681350767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061784015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13883604,0.85959023,7.1270074e-7,0.00003792626,0.00043487168,0.00084370334,0.0000615193,0.00006456337,0.00013045556],"genre_scores_gemma":[0.025613187,0.9729504,0.000120059216,0.00013812652,0.00029690858,0.0000393893,0.000075597025,0.00008218139,0.00068415364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776983,0.00016870405,0.000947732,0.0005178672,0.00031255468,0.00028331525],"domain_scores_gemma":[0.99841416,0.000097064425,0.00067221344,0.00048407208,0.00013576429,0.00019671331],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041629755,0.00042011682,0.0015365136,0.0002717428,0.00008882487,0.000028618739,0.0001420638,0.00042879744,0.000034441746],"category_scores_gemma":[0.00006479475,0.00030721832,0.00028217945,0.00031846852,0.0002307607,0.00006789818,0.00007926127,0.00052733265,0.00008152213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058383346,0.0001772386,0.00011279562,0.04080615,0.00027763788,0.000032225737,0.0007550324,3.9312052e-8,0.17222172,0.000030370264,0.0019097391,0.7836187],"study_design_scores_gemma":[0.0012189186,0.0001508084,0.0000043054056,0.021551376,0.0022618815,0.00054932496,0.0003712869,0.00000808009,0.07227436,5.062245e-7,0.9008448,0.0007643551],"about_ca_topic_score_codex":0.000027569155,"about_ca_topic_score_gemma":6.9759875e-7,"teacher_disagreement_score":0.8989351,"about_ca_system_score_codex":0.000058904086,"about_ca_system_score_gemma":0.00050915394,"threshold_uncertainty_score":0.999938},"labels":[],"label_agreement":null},{"id":"W2067292160","doi":"10.2165/11586210-000000000-00000","title":"Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohnʼs Disease with no Relapse After Switching to Adalimumab","year":2010,"lang":"en","type":"article","venue":"BioDrugs","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Innovates - Health Solutions","keywords":"Infliximab; Adalimumab; Medicine; Autoimmune hepatitis; Crohn's disease; Internal medicine; Disease; Gastroenterology; Inflammatory bowel disease; Tumor necrosis factor alpha; Hepatitis; Immunology","score_opus":0.004201924402870781,"score_gpt":0.2110650540486236,"score_spread":0.20686312964575282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067292160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972819,0.00016190772,0.000015378817,0.00097349845,0.00013727756,0.00078537647,0.00009684166,0.00007459843,0.00047324097],"genre_scores_gemma":[0.99701214,0.000014284015,0.0005604232,0.0017099115,0.00004790993,0.00019612185,0.00007515189,0.00004422656,0.00033984598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859035,0.000043365828,0.00026893822,0.00035439266,0.00037324257,0.00036972904],"domain_scores_gemma":[0.998612,0.000027703018,0.00008078211,0.0006671978,0.00014104586,0.0004712791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008078586,0.0002587694,0.00029934358,0.00013731279,0.00008070305,0.000053018048,0.00012617862,0.00007727322,0.0002852569],"category_scores_gemma":[0.000073991236,0.00018210537,0.000058569825,0.00030956915,0.000040303494,0.00020140788,0.00010722557,0.00045710962,0.00011993322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017518887,0.002081295,0.93636364,0.0002226584,0.00015364746,0.0011057303,0.004846293,0.000002622286,0.028250407,0.0000398972,0.002111509,0.0073034205],"study_design_scores_gemma":[0.0043959823,0.0014237536,0.9827101,0.00052240095,0.0001229405,0.000023867118,0.00018415012,0.00012322477,0.0005974226,0.0000068882377,0.009497955,0.00039126218],"about_ca_topic_score_codex":0.0034814288,"about_ca_topic_score_gemma":0.00032965926,"teacher_disagreement_score":0.04634652,"about_ca_system_score_codex":0.00009167691,"about_ca_system_score_gemma":0.0002837755,"threshold_uncertainty_score":0.7426042},"labels":[],"label_agreement":null},{"id":"W2073194177","doi":"10.2165/00063030-200620010-00001","title":"The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases","year":2006,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Oligonucleotide; Genetic enhancement; Small interfering RNA; RNA interference; RNA; Immune system; Biology; Translation (biology); Medicine; Pharmacology; Messenger RNA; Computational biology; Gene; Immunology; Genetics","score_opus":0.023349191964029858,"score_gpt":0.3058975377542738,"score_spread":0.28254834579024396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073194177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017422147,0.9816609,3.3040243e-7,0.000016721608,0.00015146084,0.00032092043,0.00022955715,0.0000018891085,0.00019608469],"genre_scores_gemma":[0.0025188285,0.9967026,0.000005160671,0.000025633184,0.000401596,0.00003980805,0.0001316128,0.0000138005025,0.00016095466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894935,0.00018620022,0.00040134863,0.00021389006,0.0001034224,0.0001457644],"domain_scores_gemma":[0.9990687,0.000049719885,0.00025427848,0.00056597986,0.0000424782,0.00001885363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009717399,0.00021529304,0.0004682045,0.000044471177,0.000041239742,0.00001238328,0.0003365985,0.00016067988,0.0000022048812],"category_scores_gemma":[0.000009114109,0.00010171391,0.00043153187,0.00010757616,0.00014613567,0.0000011467288,0.000029472309,0.000046081183,0.000004016055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029685147,0.00024050096,0.00015260131,0.0008306172,0.00012795061,0.000008181252,0.000042996442,4.882997e-7,0.00034558098,0.000042860378,0.0072685615,0.99091],"study_design_scores_gemma":[0.000115646064,0.0003790816,0.00019475541,0.00036053295,0.00016278304,0.000003125256,0.00008685871,8.489607e-8,0.0010603374,0.0000064241876,0.99752533,0.00010501598],"about_ca_topic_score_codex":0.00003755507,"about_ca_topic_score_gemma":0.00008726559,"teacher_disagreement_score":0.990805,"about_ca_system_score_codex":0.000012844185,"about_ca_system_score_gemma":0.0001351112,"threshold_uncertainty_score":0.41477728},"labels":[],"label_agreement":null},{"id":"W2079402257","doi":"10.2165/00063030-200115050-00001","title":"C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Immunosuppression; Medicine; Therapeutic drug monitoring; Nephrotoxicity; Trough level; Transplantation; Kidney transplantation; Urology; Ciclosporin; Pharmacology; Internal medicine; Drug; Kidney; Tacrolimus","score_opus":0.2002765864096752,"score_gpt":0.4437927799303807,"score_spread":0.2435161935207055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079402257","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007223913,0.9955134,0.0001238374,0.00020692621,0.0006887214,0.002088272,0.00009911593,0.00009095393,0.00046641953],"genre_scores_gemma":[0.0016506712,0.994686,0.0006273458,0.00006128812,0.0020369084,0.00020451045,0.00027316692,0.00004331882,0.00041680943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847233,0.00008731545,0.00048766143,0.0003847856,0.00022019002,0.00034770492],"domain_scores_gemma":[0.9984027,0.0008477706,0.00029356364,0.00029812244,0.0000671996,0.000090622954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025483768,0.00039761877,0.0011970105,0.00004920045,0.00030179054,0.00005969716,0.00019203936,0.00029894448,0.00004765042],"category_scores_gemma":[0.00012478106,0.0002049587,0.00053300813,0.00019749538,0.000044452572,0.00007625628,0.00010575383,0.00039404814,0.000021257987],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062915205,0.00006719216,0.0000383644,0.0017775322,0.00028034937,0.000013337963,0.0000428656,0.0000055703454,0.000065010594,0.000016997721,0.0014123776,0.9962175],"study_design_scores_gemma":[0.00072767725,0.00017139755,0.00030743718,0.009287932,0.0016703679,0.000010619939,0.00005662231,0.00007146966,0.00011358766,0.00008095541,0.9872467,0.000255224],"about_ca_topic_score_codex":0.000086852735,"about_ca_topic_score_gemma":6.333186e-7,"teacher_disagreement_score":0.99596226,"about_ca_system_score_codex":0.00015102563,"about_ca_system_score_gemma":0.00008131467,"threshold_uncertainty_score":0.83579737},"labels":[],"label_agreement":null},{"id":"W2089502375","doi":"10.1007/s40259-012-0003-4","title":"Targeting Focal Adhesion Kinase in Fibrotic Diseases","year":2012,"lang":"en","type":"review","venue":"BioDrugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Fibrosis; Extracellular matrix; Focal adhesion; Medicine; Scleroderma (fungus); Pulmonary fibrosis; Idiopathic pulmonary fibrosis; Cancer research; Signal transduction; Pathology; Immunology; Biology; Lung; Cell biology; Internal medicine","score_opus":0.03822410845400634,"score_gpt":0.3191907090961403,"score_spread":0.28096660064213397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089502375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049402177,0.9975375,0.000004806138,0.00004482129,0.0005812562,0.0009926446,0.00025907814,0.000081647675,0.00044886375],"genre_scores_gemma":[0.0022114324,0.9944539,0.00009159878,0.00008399374,0.0014020327,0.00012860495,0.0010483204,0.00008316837,0.00049695885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779713,0.00015884136,0.00068693375,0.00047606605,0.00031471023,0.00056630763],"domain_scores_gemma":[0.99881333,0.00010344521,0.00020461156,0.00039545,0.000041630457,0.00044153616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016318633,0.00048593408,0.0015590205,0.00028799142,0.00006529221,0.000026696209,0.00017134094,0.00034959798,0.00035274832],"category_scores_gemma":[0.00010712732,0.0003705793,0.00082128396,0.00031014992,0.000077916164,0.00010851683,0.00013376366,0.00040745287,0.00055821356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050981855,0.00073627866,0.00024797945,0.08157779,0.000103486076,0.00055448845,0.000047728023,2.0997989e-7,0.000009511552,0.00011719449,0.003931149,0.9121644],"study_design_scores_gemma":[0.00030029906,0.00044961908,0.00008217954,0.038007498,0.0021202264,0.000052165036,0.00002686829,0.00001890694,7.8050164e-7,0.000008952674,0.9585258,0.000406738],"about_ca_topic_score_codex":0.000053443724,"about_ca_topic_score_gemma":6.51983e-7,"teacher_disagreement_score":0.9545946,"about_ca_system_score_codex":0.0003101455,"about_ca_system_score_gemma":0.00036748397,"threshold_uncertainty_score":0.9998746},"labels":[],"label_agreement":null},{"id":"W2131592861","doi":"10.1007/s40259-015-0130-9","title":"Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Boehringer Ingelheim","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Oncology; Cetuximab; Internal medicine; EGFR inhibitors; Cancer research; Tyrosine kinase; Pharmacology; Cancer; Receptor","score_opus":0.1326961338418439,"score_gpt":0.3950047831603708,"score_spread":0.26230864931852693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131592861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010379641,0.98845106,0.000002810821,0.00033047548,0.00087408145,0.0017088782,0.00011358042,0.00004946275,0.008365826],"genre_scores_gemma":[0.00046539117,0.99386895,0.00022292088,0.00012195064,0.00078819186,0.00030517997,0.0011533104,0.00005321548,0.0030208859],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984021,0.000091721675,0.00048233624,0.00043961938,0.0003366822,0.00024754184],"domain_scores_gemma":[0.9990993,0.00004366313,0.0002047447,0.00038197552,0.00008352136,0.00018676766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018899232,0.0003551209,0.0009612228,0.0003661665,0.00005247038,0.000037932998,0.00008031391,0.00025042117,0.00009735123],"category_scores_gemma":[0.000046659123,0.000263131,0.00026863845,0.0004294085,0.00003237079,0.000078463745,0.000029916793,0.00024600432,0.00046528404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015344078,0.0002928608,0.000014797441,0.0016902041,0.00012221588,0.00007306559,0.0001826577,9.716535e-7,0.000002955832,0.00012924908,0.029394025,0.96808165],"study_design_scores_gemma":[0.0014031157,0.0002746443,0.00000997191,0.0076948022,0.0010725143,0.000016601829,0.000051562743,0.000006790677,0.000025839792,0.000015730693,0.9891906,0.00023783647],"about_ca_topic_score_codex":0.00025145515,"about_ca_topic_score_gemma":0.000049084152,"teacher_disagreement_score":0.96784383,"about_ca_system_score_codex":0.0011358173,"about_ca_system_score_gemma":0.001111391,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W217783584","doi":"10.1007/s40259-015-0126-5","title":"Status and Prospects of Aptamers as Drug Components","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Aptamer; Drug; Pharmacotherapy; Medicine; Computational biology; Intensive care medicine; Pharmacology; Biology; Internal medicine; Genetics","score_opus":0.02908022629780935,"score_gpt":0.335241854693982,"score_spread":0.3061616283961726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W217783584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002108642,0.99666405,0.0000036955557,0.000008391594,0.00006458037,0.00035164246,0.0001142937,0.000027425906,0.00065730716],"genre_scores_gemma":[0.0031024155,0.9940523,0.001131646,0.000024790575,0.00009571042,0.000011548345,0.00062133884,0.000035580793,0.000924677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986229,0.00008669402,0.00038130558,0.0004754783,0.00018227704,0.00025132386],"domain_scores_gemma":[0.9989325,0.00000998758,0.00037386623,0.00042329868,0.00011688384,0.0001434993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018982081,0.00033371107,0.0009151549,0.000105925435,0.00003462818,0.00001580114,0.00015936272,0.00026879425,0.0000010682666],"category_scores_gemma":[0.000048931965,0.00025493128,0.000245977,0.00015542885,0.00022215751,0.000002082127,0.00018999424,0.00012310954,0.0000058887476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003328763,0.0001084641,0.00005311048,0.003432495,0.00042723794,0.0000067431542,0.00003577892,2.1662794e-8,0.003624853,0.000050898736,0.0037454057,0.9884817],"study_design_scores_gemma":[0.00012784198,0.00010124967,0.0000027035474,0.0009187874,0.00031237703,0.000017703338,0.000023513036,3.181372e-7,0.0054859123,0.00003748559,0.992673,0.0002991507],"about_ca_topic_score_codex":0.000034269982,"about_ca_topic_score_gemma":0.0000060881594,"teacher_disagreement_score":0.98892754,"about_ca_system_score_codex":0.000028708271,"about_ca_system_score_gemma":0.00017213533,"threshold_uncertainty_score":0.9999903},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.13866766770733222,"score_gpt":0.47618576035695515,"score_spread":0.33751809264962296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277879584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040604067,0.99430054,4.1272867e-7,0.00093331875,0.00016428568,0.0015537804,0.00068017206,0.000012058148,0.0023148316],"genre_scores_gemma":[0.00008853808,0.99661684,0.000010189698,0.000038879236,0.0005385281,0.00076281175,0.000027691955,0.000040106992,0.0018764395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982003,0.00019487613,0.00046854012,0.00031945825,0.00047471502,0.00034209585],"domain_scores_gemma":[0.9988558,0.00021624514,0.00014090059,0.00064441684,0.000056775953,0.000085861975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027099877,0.00028660902,0.0013396499,0.0002082659,0.000020514839,0.000009270268,0.00027335493,0.00019370334,0.0009609775],"category_scores_gemma":[0.000013758527,0.00012112733,0.0004157675,0.0003961801,0.00013630779,0.000015162048,0.000018391263,0.0001755761,0.00018151503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024277608,0.00029285986,0.00006555648,0.00612644,0.00012389754,0.000042348984,0.00029722106,3.522457e-9,0.0000014432121,0.00001872783,0.0027338997,0.9902733],"study_design_scores_gemma":[0.00065193,0.00027825913,0.00025364215,0.019181877,0.00028854606,0.00010665746,0.000034340625,1.2056748e-7,0.0000054370653,0.000003411,0.97908443,0.00011131807],"about_ca_topic_score_codex":0.0008009699,"about_ca_topic_score_gemma":0.0000817705,"teacher_disagreement_score":0.990162,"about_ca_system_score_codex":0.0011763931,"about_ca_system_score_gemma":0.0014983151,"threshold_uncertainty_score":0.99995226},"labels":[],"label_agreement":null},{"id":"W2302684203","doi":"10.1007/s40259-016-0166-5","title":"Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Panitumumab; KRAS; Cetuximab; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Targeted therapy; Medicine; Oncology; Epidermal growth factor receptor; Oncogene; Cancer; Cancer research; Internal medicine","score_opus":0.05484679178644022,"score_gpt":0.39421890560359996,"score_spread":0.33937211381715976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302684203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033472443,0.99256766,0.00002555319,0.00034120595,0.00011936204,0.0019196396,0.0015324338,0.000009722681,0.0001371625],"genre_scores_gemma":[0.0060172165,0.99173075,0.00021189591,0.00008179113,0.00011791481,0.001395431,0.0002800415,0.000023182773,0.0001417751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985371,0.00011337572,0.0005190035,0.00033032842,0.00028550214,0.00021466735],"domain_scores_gemma":[0.9988355,0.00047578072,0.00032722278,0.00019610107,0.00012993549,0.000035483976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026178846,0.00030196118,0.0019364676,0.00023558078,0.000065403816,0.000011046157,0.00013920067,0.00007572517,0.00024207257],"category_scores_gemma":[0.00003791196,0.00013745949,0.000914505,0.0007204869,0.00011099633,0.000023698152,0.000019649167,0.000112675094,0.0000041164776],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017916375,0.000264602,0.00019166531,0.0012278109,0.00784893,0.000016559687,0.0004717959,5.201361e-7,0.000009340266,0.00003809501,0.00027017383,0.98948133],"study_design_scores_gemma":[0.0050495756,0.0010258197,0.021347327,0.0039124563,0.022146828,0.00004163863,0.00023627568,0.000017426137,0.00013250226,0.000110396664,0.94548064,0.00049910974],"about_ca_topic_score_codex":0.00018205166,"about_ca_topic_score_gemma":0.00014749564,"teacher_disagreement_score":0.98898226,"about_ca_system_score_codex":0.00020212033,"about_ca_system_score_gemma":0.0004397452,"threshold_uncertainty_score":0.56054354},"labels":[],"label_agreement":null},{"id":"W2550419061","doi":"10.1007/s40259-016-0204-3","title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Immune system; Immunology; Medicine; Adverse effect; Autoimmunity; Immunotherapy; Antibody; Immune checkpoint; Cytotoxic T cell; CTLA-4; Nivolumab; T cell; Biology; Pharmacology","score_opus":0.01959998934634755,"score_gpt":0.2869797453921792,"score_spread":0.26737975604583164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054581225,0.994088,0.000001615656,0.00018023055,0.0010180702,0.0017628546,0.00015270076,0.00022865819,0.002022059],"genre_scores_gemma":[0.00041727384,0.98412937,0.000023580033,0.00005259792,0.00018227097,0.00013998628,0.00065271836,0.000168749,0.014233465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962163,0.00020937249,0.0017208777,0.00066173257,0.00056594535,0.00062577217],"domain_scores_gemma":[0.99731874,0.00012791666,0.0013556014,0.00087379874,0.00014218786,0.00018176774],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000787278,0.00082023186,0.0025080286,0.00036300655,0.00013050705,0.0000112789285,0.00030574395,0.00083578547,0.0009379983],"category_scores_gemma":[0.00012257243,0.00047580208,0.0018095218,0.00083292025,0.00023411523,0.00009572685,0.000096805816,0.0005966078,0.00062092085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069075834,0.00039822698,0.000061345825,0.0044921134,0.0057951333,0.000127913,0.00014500783,1.5807897e-8,0.00031187906,0.0000075041694,0.0009730743,0.986997],"study_design_scores_gemma":[0.004549214,0.00037795454,0.00046145782,0.09405254,0.0017188154,0.00013704956,0.000030610954,2.4430733e-7,0.00015665623,0.000004643272,0.8978357,0.0006751343],"about_ca_topic_score_codex":0.0001009704,"about_ca_topic_score_gemma":0.0000050513863,"teacher_disagreement_score":0.98632187,"about_ca_system_score_codex":0.0010269943,"about_ca_system_score_gemma":0.0009373314,"threshold_uncertainty_score":0.99997526},"labels":[],"label_agreement":null},{"id":"W2613074462","doi":"10.1007/s40259-017-0219-4","title":"Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents","year":2017,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Concordance; Immunoassay; Cross-reactivity; Infliximab; Antibody; Rheumatoid arthritis; Internal medicine; Cross reactions; Immunology; Tumor necrosis factor alpha","score_opus":0.09935088227926661,"score_gpt":0.395455338091884,"score_spread":0.29610445581261735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613074462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984454,0.0005216785,0.00004309891,0.00016321879,0.00010755205,0.0003124876,0.00009989426,0.000008485511,0.00029819223],"genre_scores_gemma":[0.9988784,0.000033181546,0.0009355702,0.000030039528,0.000010417253,0.000003490185,0.000009248256,0.000007149959,0.00009246375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983992,0.0005424585,0.00029728113,0.00037938525,0.00017108435,0.00021058021],"domain_scores_gemma":[0.9981078,0.00005668439,0.00048380147,0.00093180937,0.00039444407,0.000025462998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021486385,0.00016688331,0.0004513293,0.00010998522,0.000362895,0.000042305615,0.0003988792,0.00009680399,0.00004599263],"category_scores_gemma":[0.0005041592,0.00010022345,0.000087565284,0.00021549454,0.0008697678,0.00018870781,0.00021971768,0.00017154022,0.0000010758482],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011326941,0.00013216547,0.2865266,0.000018899882,0.0005997904,2.7796236e-7,0.0002406645,0.000023930143,0.7062696,0.000034893073,0.000016844471,0.006023066],"study_design_scores_gemma":[0.0004680688,0.00005410368,0.61408776,0.000036153113,0.0010068758,0.000004455067,0.00006823883,0.00024337858,0.38377386,0.000032924894,0.00012437317,0.0000997991],"about_ca_topic_score_codex":0.0009983102,"about_ca_topic_score_gemma":0.00012196144,"teacher_disagreement_score":0.32756117,"about_ca_system_score_codex":0.00003403135,"about_ca_system_score_gemma":0.00010141052,"threshold_uncertainty_score":0.40869936},"labels":[],"label_agreement":null},{"id":"W2896685834","doi":"10.1007/s40259-018-0309-y","title":"Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier","year":2018,"lang":"en","type":"article","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"Government of Canada","keywords":"Transcytosis; Biomanufacturing; Gene delivery; Blood–brain barrier; Transferrin receptor; Genetic enhancement; Nanocarriers; Medicine; Biology; Neuroscience; Computational biology; Immunology; Receptor; Central nervous system; Gene; Pharmacology; Drug; Biotechnology","score_opus":0.01483342197156779,"score_gpt":0.28583305590108515,"score_spread":0.27099963392951737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896685834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249685,0.005685263,0.0006554214,0.0007453362,0.00010300815,0.00017848221,0.000079975165,0.000016950953,0.000038697417],"genre_scores_gemma":[0.99588096,0.0022769535,0.00063482625,0.00067576166,0.00014688433,0.000021557858,0.000013904253,0.000013323436,0.0003358062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937737,0.000017333656,0.0001395815,0.00021564032,0.00005564066,0.00019440934],"domain_scores_gemma":[0.9994746,0.000022473941,0.00006512977,0.00029928325,0.00012154102,0.000016959351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016422821,0.000113024966,0.00009984998,0.000021642047,0.00013239625,0.000019933253,0.00022376544,0.00013240837,0.000005321326],"category_scores_gemma":[0.000029961673,0.0000765369,0.000065895685,0.000059406528,0.00041082082,0.0000032127816,0.00009568508,0.000036193596,0.0000015930299],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009729505,0.000018637065,0.0008733839,0.0000058822793,0.00009718465,1.6464655e-7,0.00028605876,2.6781535e-7,0.9469309,0.00003061585,0.00095806527,0.050701562],"study_design_scores_gemma":[0.00039750713,0.0005139336,0.00029522242,0.0000061940777,0.0000101032065,0.00000444274,0.00070841215,0.000024404511,0.90137494,0.00010050302,0.096464254,0.00010005871],"about_ca_topic_score_codex":0.00001805281,"about_ca_topic_score_gemma":0.000018158571,"teacher_disagreement_score":0.09550619,"about_ca_system_score_codex":0.0000020122875,"about_ca_system_score_gemma":0.000025658785,"threshold_uncertainty_score":0.31210843},"labels":[],"label_agreement":null},{"id":"W2905052297","doi":"10.1007/s40259-018-0325-y","title":"Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies","year":2018,"lang":"en","type":"review","venue":"BioDrugs","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hereditary angioedema; Medicine; C1-inhibitor; Dosing; Tolerability; Kallikrein; Pharmacokinetics; Angioedema; Pharmacology; Pharmacodynamics; Internal medicine; Immunology; Adverse effect","score_opus":0.1589567030262765,"score_gpt":0.4415890634976389,"score_spread":0.28263236047136236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905052297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023628898,0.9948738,0.000009336252,0.00040251293,0.00021925727,0.0039926367,0.00020415157,0.000021278684,0.000040717747],"genre_scores_gemma":[0.0004038656,0.9975681,0.0004538056,0.000071334565,0.0006003951,0.0003757664,0.00011055473,0.00004145153,0.0003747498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788356,0.00009009624,0.0010524079,0.000438187,0.00030099493,0.00023477589],"domain_scores_gemma":[0.99724835,0.0009762161,0.0008097246,0.0005366563,0.00033003994,0.00009899136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004376372,0.000409701,0.0024912462,0.000091554815,0.00009192936,0.0000067032256,0.000114288836,0.00015061781,0.000020152249],"category_scores_gemma":[0.00033694608,0.00019213272,0.00060167967,0.00028341642,0.0005576664,0.000040400206,0.000038354323,0.00006991512,0.0000030660124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002289512,0.0007213156,0.000035897556,0.20871587,0.0010151439,0.000009188551,0.0003795547,1.0451696e-8,3.640147e-7,0.000038222355,0.004219957,0.78463554],"study_design_scores_gemma":[0.0026370538,0.007159389,0.000024415274,0.110527635,0.011239099,0.0001463205,0.00015493721,0.0000057834727,0.000025838948,0.000017365182,0.86781615,0.0002459931],"about_ca_topic_score_codex":0.00004072921,"about_ca_topic_score_gemma":0.000015627393,"teacher_disagreement_score":0.8635962,"about_ca_system_score_codex":0.00008193368,"about_ca_system_score_gemma":0.00066441885,"threshold_uncertainty_score":0.7834945},"labels":[],"label_agreement":null},{"id":"W2923414225","doi":"10.1007/s40259-019-00347-4","title":"PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Cancer; Oncology; Pharmacotherapy; Internal medicine","score_opus":0.04552099282661187,"score_gpt":0.3574579287860135,"score_spread":0.31193693595940164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923414225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.3142436e-7,0.98423296,0.000004073631,0.0009943456,0.0004725369,0.0029295257,0.00008215509,0.000032428998,0.011251155],"genre_scores_gemma":[0.00000952736,0.99571365,0.00011125451,0.0010471854,0.0003573751,0.0005329907,0.000060900333,0.000053046435,0.0021140454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799204,0.00019821976,0.00081380806,0.00040636858,0.00035856405,0.00023099773],"domain_scores_gemma":[0.9983079,0.00017726807,0.0006494876,0.00070136314,0.000084976054,0.00007905112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514173,0.0003597708,0.0021981425,0.00015648082,0.000048505954,0.00001836566,0.00019021875,0.00016463765,0.0006656626],"category_scores_gemma":[0.000036246634,0.00020393317,0.00050212553,0.00047345628,0.00018477393,0.000044395052,0.00010610138,0.0003064881,0.00006844507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000353744,0.00002075974,0.000019857865,0.22702117,0.00058563,0.000006651648,0.000061013245,1.8275191e-8,2.10376e-7,0.00048131318,0.046599094,0.7251689],"study_design_scores_gemma":[0.0015762139,0.00001885706,0.00000897431,0.20967817,0.0029653714,0.000033588385,0.000012804804,0.000001468072,0.0000011914522,0.000017147333,0.7855277,0.00015852237],"about_ca_topic_score_codex":0.0000474952,"about_ca_topic_score_gemma":0.0000017733507,"teacher_disagreement_score":0.7389286,"about_ca_system_score_codex":0.00009613201,"about_ca_system_score_gemma":0.00021682335,"threshold_uncertainty_score":0.8316154},"labels":[],"label_agreement":null},{"id":"W2930500067","doi":"10.1007/s40259-019-00346-5","title":"Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting","year":2019,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Stockholms Läns Landsting","keywords":"Biosimilar; Market share; Medical prescription; Etanercept; Pharmacy; Prior authorization; Business; Reimbursement; Medicine; Quarter (Canadian coin); Marketing; Family medicine; Public economics; Health care; Economics; Economic growth; Nursing","score_opus":0.017447343844829443,"score_gpt":0.298849918284737,"score_spread":0.28140257443990757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930500067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848075,0.0022778704,0.0000046704167,0.007430138,0.00019207087,0.0003570336,0.00012701542,0.000023597937,0.0011068272],"genre_scores_gemma":[0.9974528,0.00058184273,0.00009741397,0.0011943354,0.000058572976,0.000013437797,0.00001897494,0.00000986662,0.0005727814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828607,0.0005907639,0.00030779906,0.0003675954,0.00008986209,0.00035793023],"domain_scores_gemma":[0.9986047,0.0008096507,0.00024391511,0.0002566737,0.00005121354,0.000033846398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010638373,0.00022297901,0.00033173015,0.00010602396,0.00013217297,0.000084733794,0.00022229238,0.00023593161,0.00008463009],"category_scores_gemma":[0.0004897172,0.00013488576,0.000044147346,0.00014559031,0.00036118831,0.00013661722,0.00013197692,0.00040294314,0.000012939128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111960326,0.00008851798,0.9771655,0.000115393814,0.00013753759,0.0000031066631,0.0011511046,1.5181092e-7,0.0023737985,0.0013117935,0.0029242462,0.014616856],"study_design_scores_gemma":[0.0010023745,0.00031742026,0.83815634,0.00013494081,0.00014029795,0.000029589664,0.0029270423,0.000048207516,0.0016914549,0.00060156797,0.15455413,0.00039664848],"about_ca_topic_score_codex":0.00020305539,"about_ca_topic_score_gemma":0.00009533692,"teacher_disagreement_score":0.15162988,"about_ca_system_score_codex":0.000052767144,"about_ca_system_score_gemma":0.000040235656,"threshold_uncertainty_score":0.5500482},"labels":[],"label_agreement":null},{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","score_opus":0.04080093537706545,"score_gpt":0.28074100667087143,"score_spread":0.23994007129380598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954341438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014439893,0.9755358,0.0000028842808,0.00012538389,0.0009947588,0.0019455948,0.0069248285,0.000014381125,0.00001645456],"genre_scores_gemma":[0.0039767884,0.99407023,0.000023128041,0.000013342367,0.00015612447,0.00030913067,0.0006131505,0.00003559155,0.0008024979],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844193,0.00021443442,0.0006151392,0.00040648188,0.000045797824,0.00027621802],"domain_scores_gemma":[0.99738336,0.0015102754,0.00050217146,0.0005261723,0.000046111214,0.000031942192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021075914,0.00045102165,0.0012530918,0.000118224736,0.00020581321,0.000022455979,0.00018056549,0.00027650248,0.000053718657],"category_scores_gemma":[0.000049875096,0.00022161793,0.0004928327,0.00012496675,0.00039379447,0.000039061353,0.0000767556,0.000080880156,0.00001803585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037854898,0.00023018935,0.00009496553,0.004344025,0.0020018544,0.0000032145792,0.00084337604,4.432663e-8,0.00002975906,0.00022303968,0.00054014474,0.99131083],"study_design_scores_gemma":[0.0016912926,0.000655104,0.00024301124,0.002033919,0.0067084176,0.000036238445,0.00012419373,0.000001035936,0.00023884703,0.00002710742,0.9880186,0.0002222561],"about_ca_topic_score_codex":0.000087559754,"about_ca_topic_score_gemma":0.000025929066,"teacher_disagreement_score":0.99108857,"about_ca_system_score_codex":0.000069698865,"about_ca_system_score_gemma":0.00014463525,"threshold_uncertainty_score":0.90373164},"labels":[],"label_agreement":null},{"id":"W2961547340","doi":"10.1007/s40259-019-00366-1","title":"Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Drug; Therapeutic drug monitoring; Personalized medicine; Monoclonal antibody; Pharmacodynamics; Dosing; Pharmacokinetics; Crohn's disease; Precision medicine; Efficacy; Disease; Pharmacotherapy; Pharmacology; Immunology; Intensive care medicine; Internal medicine; Bioinformatics; Antibody; Pathology","score_opus":0.10793292692231948,"score_gpt":0.40406737536733095,"score_spread":0.29613444844501147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961547340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023586499,0.9709499,0.0000111445415,0.0009044142,0.00017914335,0.0027191394,0.0013399894,0.000039194634,0.00027059304],"genre_scores_gemma":[0.0016237698,0.99125886,0.00011647503,0.00007269082,0.0003441962,0.00029955708,0.002967654,0.00007607327,0.0032407232],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970186,0.00013537481,0.0011985915,0.000626217,0.00050423713,0.0005170084],"domain_scores_gemma":[0.99751616,0.0008334724,0.00051312696,0.000537338,0.0002660011,0.0003339286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004202461,0.00058741914,0.0021603184,0.00074972975,0.000109259556,0.00001795198,0.00033128296,0.00023896017,0.0001119246],"category_scores_gemma":[0.00024528915,0.00039449308,0.0008786236,0.0003737327,0.0004560317,0.00010919453,0.00012984875,0.00042984335,0.000023550645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001688259,0.0008695516,0.23283505,0.41614217,0.0020218447,0.00004679777,0.0035771716,0.0000039673605,0.00055856846,0.02214891,0.0116540035,0.3084537],"study_design_scores_gemma":[0.001256999,0.00014587372,0.09032697,0.030727617,0.0013348575,0.000012688089,0.0002006057,0.000020654239,0.000013610527,0.00022809631,0.87522125,0.0005107597],"about_ca_topic_score_codex":0.00018095213,"about_ca_topic_score_gemma":0.000012860929,"teacher_disagreement_score":0.86356723,"about_ca_system_score_codex":0.00025452176,"about_ca_system_score_gemma":0.0009282863,"threshold_uncertainty_score":0.9998507},"labels":[],"label_agreement":null},{"id":"W3094124122","doi":"10.1007/s40259-020-00451-w","title":"Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministère de l'Agriculture, des Pêcheries et de l'Alimentation; University of Calgary; Western University","funders":"","keywords":"Ustekinumab; Medicine; Interleukin 23; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Immunology; Inflammation; Immune system; Pathogenesis; Disease; Clinical trial; Interleukin 17; Internal medicine; Tumor necrosis factor alpha; Infliximab","score_opus":0.06456502656389661,"score_gpt":0.31679348668401647,"score_spread":0.25222846012011985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094124122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935011,0.0032147153,0.0000044836347,0.0009447747,0.0011383584,0.0003761364,0.0004461487,0.00005995662,0.00031428953],"genre_scores_gemma":[0.9984897,0.00033327102,0.000036425256,0.00028359523,0.00023378771,0.000030284546,0.00018155835,0.000015662996,0.00039575138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970355,0.0011531945,0.001162622,0.00035021568,0.000045390258,0.00025308604],"domain_scores_gemma":[0.99874014,0.00054843945,0.0003354576,0.0002498316,0.000028979253,0.00009717769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013538635,0.00019358449,0.0006224097,0.00009388576,0.000043560758,0.000007255415,0.00019123033,0.000288547,0.00025832545],"category_scores_gemma":[0.0011422848,0.00015870067,0.0003906072,0.00011947633,0.00017921856,0.000060380815,0.00008374306,0.00016621244,0.00068888406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033573264,0.00052425946,0.85069937,0.00011483186,0.0004976017,0.00007480324,0.0011862579,0.0000032185355,0.06332503,0.00034264463,0.020368038,0.05950662],"study_design_scores_gemma":[0.013431443,0.0005261569,0.7222704,0.00016814921,0.00054884807,0.0000031089025,0.0005552023,0.000010110654,0.084691174,0.00015666983,0.17702484,0.00061386556],"about_ca_topic_score_codex":0.000017096016,"about_ca_topic_score_gemma":0.000007759669,"teacher_disagreement_score":0.1566568,"about_ca_system_score_codex":0.00001891496,"about_ca_system_score_gemma":0.00015274431,"threshold_uncertainty_score":0.88544405},"labels":[],"label_agreement":null},{"id":"W3132376226","doi":"10.1007/s40259-020-00464-5","title":"Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen UK; Arthritis Society; Psoriasis Association","keywords":"Medicine; Nice; Specialty; Excellence; Equity (law); Alternative medicine; Health care; Family medicine; Intensive care medicine; Political science","score_opus":0.04720052022437258,"score_gpt":0.30890214784455794,"score_spread":0.26170162762018534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132376226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311763,0.00456163,0.00014933512,0.00024044412,0.0010140666,0.00025021916,0.00023930121,0.00010038566,0.00032699917],"genre_scores_gemma":[0.99615264,0.0009103371,0.0021821728,0.000107476444,0.000035728262,0.000017415667,0.0005083261,0.000018242758,0.00006765497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538726,0.0019570098,0.0011543217,0.0007967011,0.00005563441,0.00064909743],"domain_scores_gemma":[0.9980751,0.00072213594,0.00042669568,0.0005213159,0.00017748126,0.000077253106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012520752,0.00037755346,0.0009630266,0.00015985424,0.00017614491,0.00004694411,0.00031943506,0.0007172086,0.000101676706],"category_scores_gemma":[0.0011264433,0.0003166717,0.00017851933,0.0002503299,0.0015270474,0.00007271702,0.00027264023,0.00045373174,0.000023075989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006509694,0.0004283352,0.98270833,0.000029417228,0.00021311181,0.00020080294,0.00023836696,0.00003218169,0.007272831,0.0014368697,0.00023723328,0.0065515703],"study_design_scores_gemma":[0.005753619,0.0006271364,0.97571033,0.00019433125,0.0001023676,0.00084308395,0.001510526,0.00007614058,0.012708964,0.00018635152,0.0018787652,0.00040835756],"about_ca_topic_score_codex":0.00046821465,"about_ca_topic_score_gemma":0.0008292862,"teacher_disagreement_score":0.006997954,"about_ca_system_score_codex":0.00006049621,"about_ca_system_score_gemma":0.0001862914,"threshold_uncertainty_score":0.99992853},"labels":[],"label_agreement":null},{"id":"W3167186946","doi":"10.1007/s40259-021-00486-7","title":"Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Women and Children's Health Research Institute","keywords":"Spinal muscular atrophy; Duchenne muscular dystrophy; SMA*; Exon skipping; Medicine; Dystrophin; Neuromuscular disease; Muscular dystrophy; Antisense therapy; Motor neuron; Weakness; Bioinformatics; Genetic enhancement; Exon; Internal medicine; Disease; Biology; Surgery; Genetics; Gene; microRNA; Alternative splicing","score_opus":0.061684812040391196,"score_gpt":0.4081047040783568,"score_spread":0.34641989203796564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167186946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02886173,0.9653127,0.00029716032,0.00027069103,0.000103245926,0.005088511,0.000041431864,0.000020031723,0.0000044893877],"genre_scores_gemma":[0.0009105922,0.9962028,0.0012808241,0.00005030955,0.00010884352,0.0011749464,0.00015968928,0.00009002577,0.000021939588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960963,0.00083012716,0.00097320526,0.000890202,0.0007482298,0.00046192567],"domain_scores_gemma":[0.99812603,0.00013291901,0.0004562276,0.0008547035,0.00025695114,0.0001731593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011846217,0.0005458782,0.00194847,0.000334415,0.00034906864,0.00007351861,0.0002401681,0.00012554554,0.0000074853183],"category_scores_gemma":[0.0004328106,0.00036390696,0.0006728777,0.0005619897,0.0002746766,0.000099515215,0.0007153502,0.00067069137,7.963662e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020142603,0.00014349243,0.000007849916,0.102027416,0.00013749687,0.00006896705,0.00010835158,4.007669e-7,0.004758536,0.000010474958,0.000023056946,0.8926938],"study_design_scores_gemma":[0.0011899614,0.00034716076,0.0003763385,0.18771514,0.0010968279,0.000111756286,0.000036088117,0.000016406353,0.0003389174,0.0000734586,0.80830085,0.00039711472],"about_ca_topic_score_codex":0.000017228289,"about_ca_topic_score_gemma":0.0000015067855,"teacher_disagreement_score":0.8922967,"about_ca_system_score_codex":0.00008527484,"about_ca_system_score_gemma":0.0004852977,"threshold_uncertainty_score":0.99988127},"labels":[],"label_agreement":null},{"id":"W3212746417","doi":"10.1007/s40259-021-00507-5","title":"Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; American Gastroenterological Association","keywords":"Medicine; Inflammatory bowel disease; Drug; Meta-analysis; Antibody; Pharmacotherapy; Pharmacology; Disease; Immunology; Internal medicine","score_opus":0.041898538352883714,"score_gpt":0.331977762686112,"score_spread":0.2900792243332283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212746417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047401013,0.99555194,0.000013954723,0.000037399208,0.000051590298,0.0031053855,0.00068760756,0.000028044207,0.000050047747],"genre_scores_gemma":[0.00034762447,0.9903569,0.000029235796,0.00063011923,0.000042200187,0.00085793284,0.007321736,0.000054958604,0.00035926333],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9951579,0.0014651406,0.0016831306,0.0009593282,0.00030162596,0.0004328633],"domain_scores_gemma":[0.99709433,0.000039330844,0.0010507401,0.0013822588,0.00014641846,0.00028689826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010520387,0.0008137448,0.004585075,0.0003992638,0.00009299056,0.00011239486,0.0005002567,0.0003365933,0.000065788154],"category_scores_gemma":[0.00035584965,0.00060157466,0.0029336072,0.0005539832,0.00009970093,0.00002079003,0.0003764054,0.00021931049,0.00005633563],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000039424012,0.000072610266,0.00011973063,0.9610371,0.03735416,0.00032976762,0.000013719599,0.0000044046155,0.000005647896,0.000016980948,0.00084553735,0.00019639915],"study_design_scores_gemma":[0.00023370587,0.000010782599,0.00047536823,0.042377204,0.86343294,0.000019073697,0.000025836145,0.00002297036,0.000003360541,0.0000023810387,0.09211858,0.0012777695],"about_ca_topic_score_codex":0.0000023650875,"about_ca_topic_score_gemma":0.0000115970315,"teacher_disagreement_score":0.9186599,"about_ca_system_score_codex":0.000070264985,"about_ca_system_score_gemma":0.0003149579,"threshold_uncertainty_score":0.99964356},"labels":[],"label_agreement":null},{"id":"W34856137","doi":"10.2165/0063030-200822060-00003","title":"Embryonic Stem Cell Transplantation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pluripotent Stem Cells Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Transplantation; Stem cell; Medicine; Myocyte; Progenitor cell; Embryonic stem cell; Cell therapy; Angiogenesis; Stem-cell therapy; Internal medicine; Pathology; Biology; Cell biology","score_opus":0.03194788123583159,"score_gpt":0.2997860719150581,"score_spread":0.26783819067922654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34856137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013519224,0.99500686,0.000059308353,0.000008678867,0.00019610005,0.0005606822,0.0001789936,0.00002109971,0.003833113],"genre_scores_gemma":[0.000036848105,0.9834715,0.0000577563,0.000019525172,0.00026338236,0.00007929342,0.0015046982,0.000068683476,0.014498314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820364,0.00019564177,0.00033662625,0.0006032095,0.00026918505,0.0003916861],"domain_scores_gemma":[0.9990998,0.00002184629,0.00016346334,0.0005396533,0.000047708738,0.00012756311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010911659,0.00037276308,0.0006051514,0.000120455654,0.00008943023,0.000025351734,0.0004592787,0.00052746997,0.00002275084],"category_scores_gemma":[0.0000030146489,0.00032147343,0.0004958496,0.00016632609,0.00006951147,0.000002146657,0.00008586983,0.00023123465,0.00062492257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020694508,0.00008469851,0.000002531307,0.015904319,0.00013160305,0.00008898076,0.000029442728,9.519278e-7,0.0015415684,0.00000443381,0.01743768,0.9647531],"study_design_scores_gemma":[0.00018832753,0.000074871954,0.0000015007049,0.00067370356,0.00010173508,0.00018999432,0.0000048630054,6.187983e-7,0.0022750862,3.45279e-7,0.9961485,0.00034044025],"about_ca_topic_score_codex":0.000006070776,"about_ca_topic_score_gemma":0.0000028067377,"teacher_disagreement_score":0.97871083,"about_ca_system_score_codex":0.00004202501,"about_ca_system_score_gemma":0.00042800093,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W4200032396","doi":"10.1007/s40259-021-00512-8","title":"A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"UCB Pharma; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Certolizumab pegol; Medicine; Calprotectin; Internal medicine; Confidence interval; Crohn's disease; Odds ratio; Area under the curve; Population; Placebo; Gastroenterology; Pharmacokinetics; Inflammatory bowel disease; Disease; Adalimumab","score_opus":0.03376399519034329,"score_gpt":0.3145580637676515,"score_spread":0.2807940685773082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200032396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104786,0.00004000345,0.006006587,0.00082687644,0.00015254793,0.0008748297,0.0009902732,0.000018881003,0.00004216904],"genre_scores_gemma":[0.9915343,0.0000045007323,0.006704502,0.0003386119,0.00016396947,0.00026243503,0.00012314747,0.000022196613,0.0008463734],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985212,0.00016349468,0.00042580752,0.00052662427,0.00013874314,0.00022413884],"domain_scores_gemma":[0.998418,0.00003590234,0.00006614794,0.0006922411,0.00034668707,0.00044106983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024687033,0.00013943495,0.00016466492,0.000036824145,0.00004932295,0.00001365086,0.00015537758,0.00011078343,0.000012106534],"category_scores_gemma":[0.0019761873,0.00014384149,0.00022220273,0.000075521384,0.00005306579,0.0000040168898,0.00016920619,0.00003982801,0.00001036064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14340687,0.0019476337,0.06801974,0.00073668273,0.00018921125,0.000712991,0.00044855446,0.0031055238,0.7435599,0.00017482898,0.025144307,0.0125537375],"study_design_scores_gemma":[0.0034374176,0.0006445666,0.9121736,0.000080926155,0.00015405039,0.00001910549,0.000053357973,0.009137499,0.056190223,0.00051317766,0.017051164,0.0005449032],"about_ca_topic_score_codex":0.0000014955187,"about_ca_topic_score_gemma":0.000016513406,"teacher_disagreement_score":0.8441539,"about_ca_system_score_codex":0.000032069343,"about_ca_system_score_gemma":0.00067964895,"threshold_uncertainty_score":0.5865686},"labels":[],"label_agreement":null},{"id":"W4310776690","doi":"10.1007/s40259-022-00568-0","title":"The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries","year":2022,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; China; Medicine; Biopharmaceutical; European union; Business; Product (mathematics); International trade; Biotechnology; Geography","score_opus":0.02814807893878446,"score_gpt":0.29967549266217763,"score_spread":0.2715274137233932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310776690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955738,0.0389355,0.000005541793,0.0014889966,0.00048199622,0.0002817951,0.0020473404,0.00001712591,0.0010036689],"genre_scores_gemma":[0.99692917,0.0020375797,0.00020858672,0.000540913,0.000009607562,0.000008297285,0.000034615605,0.0000056577055,0.00022557237],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863935,0.00049507624,0.00035134165,0.00023138236,0.000071242735,0.0002116311],"domain_scores_gemma":[0.9989986,0.00036630893,0.0002556318,0.00029831397,0.00005856195,0.00002261427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078237406,0.00015023677,0.00038443276,0.000045337692,0.00017468602,0.000005230463,0.00030737495,0.00015577719,0.00051796983],"category_scores_gemma":[0.000084480176,0.000090059824,0.00012337376,0.00016197606,0.0006261227,0.000021917713,0.0002019718,0.0001433439,0.0000018056439],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032361206,0.0036493368,0.32958132,0.002025615,0.0073927147,0.0000404014,0.0031776107,0.000023516573,0.2710113,0.12815534,0.12279215,0.09978949],"study_design_scores_gemma":[0.0047077457,0.0047517866,0.17416413,0.00012873112,0.00057789986,0.000058284088,0.004804013,0.000030427627,0.40140444,0.0066099176,0.40210506,0.0006575485],"about_ca_topic_score_codex":0.000046953464,"about_ca_topic_score_gemma":0.000015938833,"teacher_disagreement_score":0.2793129,"about_ca_system_score_codex":0.000018030221,"about_ca_system_score_gemma":0.000040829138,"threshold_uncertainty_score":0.56714064},"labels":[],"label_agreement":null},{"id":"W4360601016","doi":"10.1007/s40259-023-00589-3","title":"Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health and Medical Research Fund; Medical Research Council; University of Hong Kong; National Institute for Health and Care Research; Australian Government; National Health and Medical Research Council; European Commission; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Interrupted time series; Interrupted Time Series Analysis; Consumption (sociology); Demography; Internal medicine; Tumor necrosis factor alpha","score_opus":0.02306556960911271,"score_gpt":0.3292944411009679,"score_spread":0.3062288714918552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360601016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974874,0.000816495,0.000040207677,0.00069416617,0.0001785104,0.0003072545,0.00019378678,0.0001269895,0.00015513663],"genre_scores_gemma":[0.9975277,0.00048482325,0.0010184323,0.0001407549,0.000039524057,0.000026888036,0.00026006316,0.000026026215,0.0004757694],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997708,0.00032426568,0.0006715362,0.0006737819,0.000099075485,0.00052333187],"domain_scores_gemma":[0.99866855,0.00031887883,0.00028055822,0.0005397827,0.00011423528,0.00007797431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007631847,0.00036612927,0.0008152126,0.0013793914,0.00012025315,0.000049309056,0.0002478213,0.00044546716,0.000497718],"category_scores_gemma":[0.0003135783,0.0002836912,0.00027380115,0.0018755028,0.0005981078,0.00032765372,0.00016756999,0.00037277158,0.000109507826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058801365,0.001864076,0.41155076,0.00027825395,0.0069570174,0.00006377898,0.005128696,0.00027297068,0.5338472,0.003214245,0.0076407003,0.023302162],"study_design_scores_gemma":[0.005162547,0.0028184494,0.8990749,0.0002533766,0.0010765357,0.000060672417,0.00061656896,0.0016788145,0.082233176,0.0005326861,0.005372234,0.0011200529],"about_ca_topic_score_codex":0.00015183205,"about_ca_topic_score_gemma":0.00004966936,"teacher_disagreement_score":0.48752415,"about_ca_system_score_codex":0.0001225996,"about_ca_system_score_gemma":0.00007527038,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W4362507438","doi":"10.1007/s40259-023-00592-8","title":"Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"ZonMw","keywords":"Medicine; Internal medicine; Rheumatoid arthritis; Etanercept; Cohort; Adverse effect; Adalimumab; Infliximab; Rituximab; Discontinuation; Disease; Pediatrics","score_opus":0.12201455600774835,"score_gpt":0.35177126870530334,"score_spread":0.229756712697555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895579,0.0046418696,0.000010432165,0.003918819,0.00036125493,0.00044389063,0.000387527,0.00022651191,0.0004517584],"genre_scores_gemma":[0.99262834,0.004639958,0.00021744551,0.00031976606,0.0002419555,0.00009387243,0.0016495547,0.00001413068,0.00019499281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850976,0.00011931731,0.0003285002,0.00042797124,0.00027230993,0.00034212894],"domain_scores_gemma":[0.9985015,0.0002482068,0.00008833934,0.00096253626,0.00007525338,0.00012415479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031120164,0.00015481534,0.00020708132,0.00005934744,0.00016274984,0.000072599316,0.00031476674,0.00009709376,0.0005391389],"category_scores_gemma":[0.00052146555,0.00008971994,0.00006109607,0.0003475636,0.00018069694,0.00011090321,0.00026454267,0.00019279234,0.0005378461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017130352,0.00038595195,0.6845701,0.000045124136,0.00070073764,0.0013632617,0.0017817123,9.237416e-7,0.019303052,0.00012486201,0.07322718,0.21678407],"study_design_scores_gemma":[0.0025936547,0.001380536,0.61686885,0.0005289889,0.000031093048,0.00011923702,0.004042661,0.0005763346,0.010906554,0.0012604817,0.36112863,0.00056297873],"about_ca_topic_score_codex":0.00016636374,"about_ca_topic_score_gemma":0.00005450581,"teacher_disagreement_score":0.28790143,"about_ca_system_score_codex":0.000018856588,"about_ca_system_score_gemma":0.0000987998,"threshold_uncertainty_score":0.6913103},"labels":[],"label_agreement":null},{"id":"W4388902238","doi":"10.1007/s40259-023-00630-5","title":"Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Celltrion","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Biosimilar; Dosing; Adverse effect; Randomized controlled trial; Psoriasis; Tolerability; Internal medicine; Dermatology; Adalimumab","score_opus":0.04463726408912411,"score_gpt":0.3397974502253265,"score_spread":0.2951601861362024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993409,0.0004862133,0.000021140766,0.0007897529,0.00067497534,0.0034503753,0.00070156105,0.000057838704,0.00040917078],"genre_scores_gemma":[0.9986297,0.00030590556,0.00014201154,0.00006628539,0.00003286802,0.00013928165,0.00007320533,0.000024640278,0.0005861078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967947,0.00064605614,0.001177886,0.00069975073,0.0001251358,0.00055646914],"domain_scores_gemma":[0.9977064,0.0011776754,0.00036820935,0.0004917154,0.00015068693,0.000105310675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016611059,0.00039268186,0.0014738557,0.00053229346,0.00012939154,0.000019916806,0.0003186022,0.00026650957,0.00007587575],"category_scores_gemma":[0.00037292644,0.0003031415,0.0001913711,0.0009531698,0.00024454907,0.000096257005,0.00020023026,0.00035929077,0.000025971585],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97088146,0.0017030275,0.00006996475,0.000042893684,0.0012190156,0.00004067534,0.0016780547,0.000036109806,0.01743956,0.00008598217,0.0012626789,0.0055405498],"study_design_scores_gemma":[0.90951216,0.00222271,0.00043901685,0.0001039162,0.00043830715,0.000008593705,0.0017558326,0.00008279959,0.08051165,0.000022850056,0.0045234496,0.00037870198],"about_ca_topic_score_codex":0.0005211662,"about_ca_topic_score_gemma":0.00024532247,"teacher_disagreement_score":0.06307209,"about_ca_system_score_codex":0.00007088396,"about_ca_system_score_gemma":0.0001617998,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W4389486878","doi":"10.1007/s40259-023-00636-z","title":"Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea","keywords":"Biosimilar; Adalimumab; Medicine; Significant difference; Intensive care medicine; Internal medicine; Rheumatoid arthritis","score_opus":0.027742553902886852,"score_gpt":0.2830068196293937,"score_spread":0.25526426572650684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389486878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995486,0.0006208299,0.000035236248,0.002315116,0.000102294885,0.00021172348,0.00097642216,0.00004547678,0.00020687141],"genre_scores_gemma":[0.99791807,0.00019385265,0.000055037013,0.00038845194,0.000004478104,0.000012094774,0.000068457186,0.000008501201,0.0013510763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809825,0.00043935428,0.0005607676,0.0003856901,0.0001287622,0.00038719745],"domain_scores_gemma":[0.9977171,0.0011927106,0.0003170219,0.00053272664,0.00021621614,0.000024236002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058391,0.00021817406,0.00079425506,0.00032302964,0.00009309051,0.000011766145,0.0004147982,0.00031659592,0.0005671155],"category_scores_gemma":[0.00047424436,0.00012344585,0.0002401112,0.0024630835,0.0010929288,0.000024363433,0.00012860603,0.00025185235,0.000016016182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049116754,0.0004337815,0.9187063,0.000091483904,0.0039073923,0.0000042200472,0.0021866688,0.0000038225307,0.06920481,0.0006245242,0.0025375308,0.0018082805],"study_design_scores_gemma":[0.00070216315,0.00020899207,0.93412524,0.00008383821,0.0009937539,6.6921837e-7,0.00039680648,0.00015054368,0.062062137,0.0002494786,0.00084533886,0.00018105794],"about_ca_topic_score_codex":0.00024189753,"about_ca_topic_score_gemma":0.00044009698,"teacher_disagreement_score":0.015418904,"about_ca_system_score_codex":0.000041910997,"about_ca_system_score_gemma":0.00008745382,"threshold_uncertainty_score":0.6209517},"labels":[],"label_agreement":null},{"id":"W4402620082","doi":"10.1007/s40259-024-00677-y","title":"Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences","keywords":"Chikungunya; Medicine; Clinical trial; European union; Virology; Alphavirus; Licensure; Virus; Internal medicine; Business","score_opus":0.0731524147698617,"score_gpt":0.46887543996479425,"score_spread":0.3957230251949325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402620082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016607948,0.9929573,0.000004182479,0.0004526451,0.00065713644,0.004423002,0.00086207816,0.00005513519,0.00042247542],"genre_scores_gemma":[0.000040082185,0.9951527,0.00009870235,0.001434976,0.0014546297,0.00041375926,0.00077860826,0.00007025083,0.0005562678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962667,0.00038862947,0.0015710716,0.0008799249,0.0006230987,0.00027054228],"domain_scores_gemma":[0.99763864,0.00027718613,0.0004643842,0.0009608016,0.00026243425,0.00039653273],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001335483,0.00050483044,0.0031694614,0.00015217206,0.000029733501,0.00003122095,0.00021816762,0.00034662575,0.0009142785],"category_scores_gemma":[0.0011564308,0.00033690938,0.001090373,0.0004082919,0.000032959157,0.000038711143,0.00017284833,0.00041180084,0.00038545366],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055102908,0.00011193307,0.000024104525,0.11988948,0.00062664243,0.000011591418,0.000028182574,5.302696e-9,9.000789e-7,0.000011685045,0.034820896,0.8444195],"study_design_scores_gemma":[0.00056726,0.00018947192,0.00056742335,0.21307398,0.025363578,0.000011301978,0.0000053678687,0.000020886024,2.663348e-7,0.00001388703,0.7599589,0.00022761861],"about_ca_topic_score_codex":0.00014507148,"about_ca_topic_score_gemma":0.000014186056,"teacher_disagreement_score":0.84419185,"about_ca_system_score_codex":0.00006772573,"about_ca_system_score_gemma":0.00083057623,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W4404773045","doi":"10.1007/s40259-024-00687-w","title":"Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Fundação para a Ciência e a Tecnologia; Universidade do Porto","keywords":"Medicine; Secukinumab; Hidradenitis suppurativa; Clinical trial; Dermatology; Quality of life (healthcare); Psoriasis; Pharmacology; Intensive care medicine; Disease; Internal medicine; Psoriatic arthritis","score_opus":0.06812192845542084,"score_gpt":0.37866150478802446,"score_spread":0.31053957633260365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404773045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010284325,0.99018574,2.4145544e-7,0.0021616907,0.00047002532,0.002135657,0.0003206512,0.000049172442,0.0045739883],"genre_scores_gemma":[0.012156435,0.9809167,0.000039391605,0.000003959074,0.00040454857,0.00046979147,0.0006320403,0.00007332556,0.0053038034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975382,0.0002335815,0.0009579995,0.00052457093,0.0003920143,0.00035364545],"domain_scores_gemma":[0.9987819,0.00022350547,0.00021739703,0.0006413065,0.00003321314,0.00010267176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000009307686,0.0006800777,0.0021146128,0.00052498805,0.000041832558,0.00005144312,0.00022218234,0.00033616222,0.00020619971],"category_scores_gemma":[0.000020879193,0.00033270317,0.0010525241,0.0007473542,0.00016177539,0.0000650905,0.000033524953,0.00032054778,0.0005375066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020995385,0.0011400746,0.000048392925,0.007072126,0.0006649502,0.049056865,0.0045459233,1.0024587e-9,0.0000013728051,0.00010981637,0.00642093,0.9309186],"study_design_scores_gemma":[0.0007192045,0.0011304503,0.00000408548,0.015141115,0.0031238517,0.03506536,0.0003322107,4.0913437e-7,0.000022826014,0.000024283549,0.94420046,0.00023575556],"about_ca_topic_score_codex":0.00013885126,"about_ca_topic_score_gemma":0.000049662773,"teacher_disagreement_score":0.93777955,"about_ca_system_score_codex":0.0005148656,"about_ca_system_score_gemma":0.000416802,"threshold_uncertainty_score":0.9999125},"labels":[],"label_agreement":null},{"id":"W4407184001","doi":"10.1007/s40259-025-00706-4","title":"TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Inflammatory bowel disease; Medicine; Molecular medicine; Internal medicine; Disease; Pharmacology; Bioinformatics; Biology","score_opus":0.011370653430036959,"score_gpt":0.29015501408293426,"score_spread":0.2787843606528973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407184001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049724105,0.99624705,0.0000145574795,0.00006815998,0.00027535125,0.0018447354,0.00042553243,0.000042266704,0.0010326266],"genre_scores_gemma":[0.000010854258,0.99154705,0.000027221855,0.00081738137,0.0003965084,0.0006779989,0.0036008423,0.00006566995,0.0028564571],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970511,0.00039915915,0.001025218,0.00085042446,0.00024816213,0.00042593887],"domain_scores_gemma":[0.998171,0.000025853435,0.000364741,0.0010799496,0.00010195213,0.00025654442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004765677,0.0006336873,0.0009062626,0.00024976645,0.000056457244,0.000036125726,0.00031000527,0.00044101095,0.00007967555],"category_scores_gemma":[0.00043476876,0.00059708377,0.0007521763,0.00026584268,0.000094768184,0.0000067759147,0.00033239793,0.0002977505,0.00021515641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100641475,0.00020871931,0.00014592445,0.4863183,0.00012031651,0.0011634986,0.000006934783,0.0000016138789,0.000014414857,0.00016542774,0.14001524,0.37173897],"study_design_scores_gemma":[0.00027184287,0.000008818761,0.00016968598,0.09215096,0.00045803635,0.000007646145,0.0000015074983,0.0000013586364,0.0000044163608,0.0000137307015,0.9063709,0.00054113363],"about_ca_topic_score_codex":0.0000025353806,"about_ca_topic_score_gemma":0.000013444398,"teacher_disagreement_score":0.76635563,"about_ca_system_score_codex":0.00010746286,"about_ca_system_score_gemma":0.0016077145,"threshold_uncertainty_score":0.99964803},"labels":[],"label_agreement":null},{"id":"W4407922422","doi":"10.1007/s40259-025-00709-1","title":"Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries","year":2025,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; National Research Foundation of Korea; Michael Smith Health Research BC","keywords":"Biosimilar; Infliximab; Adalimumab; Etanercept; Descriptive statistics; Medicine; Antirheumatic Agents; Pharmacology; Business; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha","score_opus":0.011238142126732919,"score_gpt":0.28803591462183653,"score_spread":0.2767977724951036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407922422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014497,0.0053044935,0.00004101775,0.0024366118,0.000033444798,0.00017993027,0.00031598218,0.000016251397,0.001527306],"genre_scores_gemma":[0.9970738,0.0019399326,0.0001221055,0.0004950829,0.000008718791,0.000008715795,0.0000065632357,0.0000057063708,0.00033933402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998789,0.0003300955,0.00030083378,0.00030053747,0.00003090783,0.00024859078],"domain_scores_gemma":[0.998938,0.00070703286,0.00009545024,0.0001813733,0.000046649857,0.00003145222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004691872,0.00023348132,0.00056961965,0.00077600003,0.00009344663,0.000037057478,0.00008382883,0.0002784346,0.00013767453],"category_scores_gemma":[0.00020041878,0.00015091087,0.0000957423,0.00050501234,0.0006883396,0.00006627827,0.0000836208,0.00014009365,0.0000010686417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070570093,0.0006897164,0.63056076,0.00057429046,0.0088198865,0.000007587357,0.011875921,0.00001037097,0.24417192,0.013377474,0.0054469765,0.0774081],"study_design_scores_gemma":[0.0010400501,0.00032012316,0.86355984,0.00013921846,0.0006153382,0.000008436791,0.0023807155,0.00020189803,0.12818685,0.0008623166,0.0023915535,0.000293635],"about_ca_topic_score_codex":0.001386874,"about_ca_topic_score_gemma":0.00036283766,"teacher_disagreement_score":0.23299912,"about_ca_system_score_codex":0.000051178118,"about_ca_system_score_gemma":0.00007136162,"threshold_uncertainty_score":0.6153967},"labels":[],"label_agreement":null},{"id":"W4411046742","doi":"10.1007/s40259-025-00727-z","title":"Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada","funders":"Sandoz; Diakonhjemmet","keywords":"Biosimilar; Real world evidence; Intensive care medicine; Medicine; Pharmacotherapy; Internal medicine","score_opus":0.11594011786904149,"score_gpt":0.39974440582842885,"score_spread":0.2838042879593874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411046742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015949662,0.99348676,8.380548e-7,0.00087187736,0.0007885649,0.0009201423,0.0009227095,0.000026965583,0.0028226685],"genre_scores_gemma":[0.000027150745,0.9965358,0.0006684523,0.0013059397,0.00002601024,0.000056635356,0.00017219268,0.000018482713,0.0011893404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967851,0.00070979516,0.0014712762,0.00063467753,0.000053332555,0.00034583197],"domain_scores_gemma":[0.99705,0.0018918085,0.000481796,0.00045775872,0.00007397722,0.00004468493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007371716,0.00039870295,0.0019452503,0.00047393847,0.00007036121,0.000012247503,0.00027785392,0.000959281,0.00007835758],"category_scores_gemma":[0.0004562026,0.00029724737,0.0004240191,0.0007631338,0.0004443775,0.00002609701,0.00023265352,0.0007715413,0.000017858534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028402841,0.00023081312,0.00073643913,0.0022519398,0.0001958949,0.0000020017478,0.000023028235,5.997183e-8,0.000003821516,0.0032606267,0.016182423,0.9770846],"study_design_scores_gemma":[0.00038847554,0.00021939744,0.0016630928,0.009563596,0.00047035428,0.000002732951,0.000015520545,2.4942307e-7,0.00007370167,0.00012210537,0.9872003,0.00028045732],"about_ca_topic_score_codex":0.000036087356,"about_ca_topic_score_gemma":0.000079118065,"teacher_disagreement_score":0.9768041,"about_ca_system_score_codex":0.000045267097,"about_ca_system_score_gemma":0.00020385231,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null}]}